



Review

# Sarcopenia in the Aging Process: Pathophysiological Mechanisms, Clinical Implications, and Emerging Therapeutic Approaches

Larissa Parreira Araújo <sup>1</sup> , Ana Clara Figueiredo Godoy <sup>1</sup>, Fernanda Fortes Frota <sup>1</sup> , Caroline Barbalho Lamas <sup>2</sup>, Karina Quesada <sup>1,3,4</sup>, Claudia Rucco Penteadó Detregiachi <sup>4</sup>, Adriano Cressoni Araújo <sup>1,4</sup>, Maria Angélica Miglino <sup>4</sup> , Elen Landgraf Guiguer <sup>1,3,4</sup>, Rafael Santos de Argollo Haber <sup>1</sup>, Eliana de Souza Bastos Mazuqueli Pereira <sup>4</sup>, Virgínia Cavallari Strozze Catharin <sup>1,4</sup>, Vitor Cavallari Strozze Catharin <sup>1</sup>, Lucas Fornari Laurindo <sup>5,\*</sup> and Sandra Maria Barbalho <sup>1,3,4,\*</sup>

- <sup>1</sup> Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil
  - <sup>2</sup> Department of Gerontology, School of Gerontology, Universidade Federal de São Carlos (UFSCar), São Carlos 13565-905, SP, Brazil
  - <sup>3</sup> Department of Biochemistry and Nutrition, School of Food and Technology of Marília (FATEC), Marília 17500-000, SP, Brazil
  - <sup>4</sup> Graduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil
  - <sup>5</sup> Division of Cellular Growth, Hemodynamic, and Homeostasis Disorders, Graduate Program in Medical Sciences, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo 01246-903, SP, Brazil
- \* Correspondence: lucasfornarilaurindo@gmail.com (L.F.L.); sandra.barbalho@fatec.sp.gov.br (S.M.B.)



Academic Editor: Giuseppe Coppotelli

Received: 17 September 2025

Revised: 2 December 2025

Accepted: 5 December 2025

Published: 17 December 2025

**Citation:** Araújo, L.P.; Figueiredo Godoy, A.C.; Fortes Frota, F.; Barbalho Lamas, C.; Quesada, K.; Rucco Penteadó Detregiachi, C.; Cressoni Araújo, A.; Miglino, M.A.; Landgraf Guiguer, E.; Santos de Argollo Haber, R.; et al. Sarcopenia in the Aging Process: Pathophysiological Mechanisms, Clinical Implications, and Emerging Therapeutic Approaches. *Int. J. Mol. Sci.* **2025**, *26*, 12147. <https://doi.org/10.3390/ijms262412147>

**Copyright:** © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## Abstract

In the face of population aging, sarcopenia has emerged as a significant muscle disorder characterized by the progressive loss of muscle mass, strength, and function. Chronic inflammation, oxidative stress, and mitochondrial dysfunction contribute to sarcopenia and help explain its association with comorbidities such as type 2 diabetes, obesity, and neurodegenerative diseases. Despite extensive research, there remains a need to integrate current knowledge on interventions that target these interconnected mechanisms. This review synthesizes recent evidence on the effects of resistance exercise, nutritional supplementation (high-protein intake, leucine, vitamin D, omega-3 fatty acids), and probiotic use on muscle function and inflammatory status in older adults with sarcopenia. Literature was critically analyzed to evaluate the efficacy of multicomponent strategies. The reviewed studies consistently report that combining resistance training with anti-inflammatory nutrition and targeted supplementation improves muscle strength, reduces pro-inflammatory cytokines, and supports mitochondrial function. These findings suggest that an integrated, multicomponent approach represents a promising strategy for attenuating the progression of sarcopenia and reducing its associated comorbidities.

**Keywords:** aging; muscle loss; sarcopenia; cognitive decline; neurodegenerative diseases

## 1. Introduction

Sarcopenia is defined, according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) study, as a muscle disorder characterized by progressive and generalized loss of the quality and quantity of skeletal muscle structure [1], resulting in adverse events such as difficulty in locomotion [2] and, in extreme cases, mortality [3].

Studies show that sarcopenia currently has a prevalence of 8% to 36% in individuals under 60 years of age and 10% to 27% in those over 60 years old, demonstrating an escalating trend in terms of prevalence annually [4].

Because sarcopenia is fundamentally an age-related condition, understanding how aging alters muscle homeostasis is essential to clarifying its mechanisms. Aging acts as the biological backdrop against which these structural and metabolic changes occur. Aging disrupts the balance between anabolic and catabolic pathways, leading to structural changes such as reduced type II fiber size and number, increased fat infiltration, and fewer satellite cells, which are responsible for replacing and repairing damaged muscle fibers [5–7]. This decline is attributable to alterations in systemic signaling pathways, including the transforming growth factor beta (TGF- $\beta$ ) and myogenin, which regulate satellite cell differentiation and activation. Other factors contributing to these changes include neuromuscular junction dysfunction, loss of motor units, chronic inflammation, and insulin resistance [8–12].

Sarcopenia also directly reduces the quality of life because it is closely linked to chronic conditions such as type 2 diabetes mellitus (T2DM) and obesity. A large part of the population is vulnerable to sarcopenia at some point in their lives [13,14]. Patients who may develop sarcopenia include the elderly, underweight people, and people with other chronic conditions. Moreover, individuals with T2DM are more likely to be affected by this condition, as it can aggravate metabolic disorders and compromise response to treatments [15–17].

Sarcopenia develops from various etiologies and can be characterized as primary or secondary. Primary sarcopenia is primarily associated with age, while secondary sarcopenia is influenced by risk factors related to muscle loss, such as sarcopenic obesity, cancer, malnutrition, and rheumatic diseases [18,19]. It is also essential to highlight the risk factors for primary sarcopenia as contributors to secondary sarcopenia, as a sedentary lifestyle and physical inactivity are triggers of this condition, even in early life [20].

These combined factors show that aging not only drives sarcopenia but also contributes to a broader systemic deterioration, affecting various physiological systems beyond skeletal muscle. This connection establishes a biological continuum between muscle aging and broader degenerative processes. Thus, hormonal changes associated with aging were observed to trigger muscle loss, with androgens playing a crucial role in maintaining cellular metabolic activity by suppressing catabolic processes and exerting an anti-inflammatory effect on peripheral tissues [21]. Therefore, low testosterone levels are associated with the pathophysiology and progression of age-related diseases, such as sarcopenia, thus establishing hormone replacement therapy as a pillar in the treatment of different pathologies [22–24].

Increasing evidence suggests that the mechanisms leading to muscle atrophy in sarcopenia—such as chronic inflammation, mitochondrial dysfunction, and hormonal imbalance—are also implicated in neurodegenerative processes. Thus, the muscle-brain axis has emerged as a critical focus in geroscience, linking functional decline to cognitive decline. On the other hand, it is known that advanced aging is still a crucial factor in the development of dementia, which is directly associated with disability and mortality [4,25]. Other factors, such as genetic, socioeconomic, and environmental factors, as well as physical activity and a balanced diet, are key determinants of cognitive impairment [26,27]. Geroscience offers molecular explanations for the pathophysiology of sarcopenia, frailty, and cognitive decline, encompassing several age-related processes. Studies show that muscle mass can serve as a tunable biomarker in dementia prevention. In other words, neurodegenerative changes tend to emerge with advancing age and are linked to the progressive and widespread loss of skeletal muscle, known as sarcopenia [28–30]. Parkinson's disease (PD), a movement disorder characterized by the death of dopaminergic neurons, is also shown to be a change related to muscle impairment [31]. Thus, studies show the

prevalence of sarcopenia in more than 50% of those affected by PD, which is associated with worse progression, greater motor impairment, and high frequency of falls, in addition to affecting non-motor symptom outcomes [32–34].

Sarcopenia and neurodegenerative diseases currently represent a significant socioeconomic challenge, generating high healthcare costs and a loss of functional independence and productivity, significantly reducing quality of life. Furthermore, they overload public healthcare systems, thus widening social inequalities.

Because these mechanisms overlap, studying sarcopenia and neurodegeneration together becomes essential, as understanding one can illuminate aspects of the other. Therefore, this review seeks to comprehensively review the intersection between sarcopenia and neurodegenerative diseases, considering aging, muscle loss, and cognitive decline. The detailed methodology employed for this review is presented in Appendix A.

## 2. Sarcopenia, Related Risk Factors, and Therapeutic Strategies

### 2.1. Cellular Mechanisms

#### Sarcopenia and Inflammation

Several pathologies, such as T2DM, osteoarthritis, cardiovascular diseases, and cirrhosis, are associated with sarcopenia [35]. Notwithstanding, oxidative stress and inflammation become crucial from the earliest stages through the development of its pathophysiology [36–38]. Inflammation is defined as a series of tissue responses to injury that may be associated with various pathologies [39,40]. Some authors indicate that inflammation impacts skeletal muscle mass, strength, and function. Current studies offer new insights into the molecular underpinnings of sarcopenia, specifically through a more specific inflammatory mechanism, pyroptosis, which involves apoptotic cells characterized by programmed cell death and is associated with inflammatory processes [41–45]. Pyroptosis is induced through activation of the Nucleotide-binding domain, leucine-rich repeat pyrin domain-containing protein 3 (NLRP3) inflammasome. Preclinical studies, particularly in animal models of denervation-induced muscle atrophy, indicate that NLRP3 activation stimulates the ubiquitin-proteasome system (UPS), promoting protein breakdown and subsequent muscle atrophy [46]. Additional evidence from bioinformatic analyses and mechanistic reviews supports a potential link between inflammation, pyroptosis, and sarcopenia, although direct evidence in humans remains limited [42,47].

Evidence indicates that aging-related increases in reactive oxygen species (ROS) impair mitochondrial function and muscle nutrient handling, promote protein oxidation and degradation, and lead to muscle loss. Elevated levels of inflammatory biomarkers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF- $\alpha$ ), are associated with muscle loss and decreased strength in the elderly [37,38,48,49]. In addition, the high number of surrounding pro-inflammatory cytokines, characteristic of chronic low-grade inflammation, increases TNF- $\alpha$ , IL-6, and interleukin-1 $\beta$  (IL-1 $\beta$ ), further favoring anabolic resistance and the loss of strength, muscle mass, and functionality of skeletal muscles [38].

Studies show that inflammation also interacts with immune cells, as these are linked to the development of sarcopenia. Leukocytes, including neutrophils, lymphocytes, and monocytes, modulate inflammation. Notably, monocytes are more closely associated with an increased risk of cardiovascular mortality in sarcopenic patients [50–52]. Leukocytes, on the other hand, exhibit immunological activity that increases oxidative stress and, consequently, the onset of sarcopenia by releasing cytokines and damaging muscle fibers through ROS [52].

Inflammation also disrupts muscle metabolism, contributing to insulin resistance and metabolic syndrome—both key risk factors for sarcopenia. Inflammation can also impede muscle protein synthesis and function, leading to skeletal muscle weakness and atrophy, which is closely linked to the onset of syndromes such as frailty. Muscle mass loss is a

key factor in its onset, affecting quality of life through symptoms such as unintentional weight loss, exhaustion, weakness, and poor physical performance [52,53]. Therefore, it is noted that inflammation has a close relationship with the development of sarcopenia and is present in several chronic pathologies; that is, it is a gateway for the appearance of risk factors, such as malnutrition, obesity, anabolic resistance, and mitochondrial damage, which can induce sarcopenia, especially in older individuals [54,55].

### **Sarcopenia and Oxidative Stress**

Oxidative stress is characterized by an imbalance in the production of ROS, which can damage the skeletal muscle genome. Increased oxidative stress in elderly patients is recognized as one of several risk factors for the development of sarcopenia [56–58]. Studies have shown that increased oxidative damage to proteins, lipids, and genetic material in skeletal muscle occurs with aging, as evidenced by increased lipid peroxidation, protein carbonylation, and deoxyribonucleic acid (DNA) damage [59]. Therefore, it is well established that oxidative stress plays a crucial role in age-related muscle deterioration. The age-related decline in the antioxidant capacity, combined with increased ROS production, contributes to impaired satellite cell function and reduced regenerative capacity. This oxidative damage is more prevalent in older men than in women [49,60–62].

Superoxide anion and nitric oxide are the primary free radicals present in muscle fibers, affecting the mitochondria, sarcoplasmic reticulum, sarcolemma, cytosol, and transverse tubules [62]. Among specific cellular structures, mitochondria are the primary targets of oxidative attack, as they are the main source of ROS in cells, due to their close association with the source of oxidants, their lack of histones and introns, and their less intensive repair compared to nuclear DNA [63]. Furthermore, studies on organelle aging demonstrate that increased oxidative stress in the elderly is primarily responsible for cellular damage [56]. Oxidative damage to mitochondria and proteins can also result in mitochondrial dysfunction [64,65].


Studies have shown that the decrease in muscle regeneration capacity in sarcopenia is due to oxidative damage in myoblasts, which play a crucial role in muscle regeneration by undergoing myogenic differentiation to fuse and restore damaged muscle; this process is also impaired by aging [57]. Furthermore, it is well established that increased ROS during aging coincides with the pro-oxidant effect of physical inactivity, leading to a significant increase in oxidative stress, as expected in aging muscle. Studies have shown that elevated biomarker levels were present in both resting and exercising muscles of elderly individuals [59]. The mechanisms of antioxidant defense in these older adults are still inconclusive. On the other hand, there is evidence of a decrease in the enzymatic antioxidant system in the muscles of this group, as demonstrated by lower catalase and glutathione transferase activities during senescence [66]. However, it becomes evident that although physical exercise does not completely alleviate the signs of mitochondrial aging, it has beneficial effects in combating mitochondrial dysfunction caused by oxidative stress associated with advanced aging, thus highlighting its importance in the daily lives of this population [67].

### **Sarcopenia and Mitochondrial Dysfunction**


Mitochondria are dynamic organelles that form an interconnected network that continuously undergoes fusion and fission, processes that maintain proper functioning and prevent the accumulation of damaged organelles [68,69]. The interaction between mitochondrial biogenesis and mitophagy degradation maintains healthy muscle. However, its disruption results in changes in cellular bioenergetics and consequent loss of muscle mass and function [70–72]. In other words, mitochondria serve as a crucial powerhouse in muscle fibers, so that their inability or ineffective function results in muscle impairment, characterized by mitochondrial swelling, loss of cristae, destruction of the inner membrane, and impaired respiration [73,74].

Mitochondrial dysfunction is defined as an imbalance in mitochondrial dynamics and the interruption of mitophagy. This process degrades damaged mitochondria via the lysosomal pathway, ensuring the functional health and metabolic homeostasis of cellular structures [75,76]. Additionally, the accumulation of mutations and deletions in mitochondrial DNA, along with reduced maximum O<sub>2</sub> uptake, contributes to defective energy production and increased ROS generation. Excess ROS can promote degradation of myofibrillar proteins and inhibit protein synthesis. Furthermore, the pathophysiological underlying muscle fiber atrophy resulting from mitochondrial dysfunction remains to be fully elucidated [73,77–80].

Studies also show that bioenergetics is a fundamental pillar to homeostasis, since the response to mitochondrial metabolic demand declines with age, resulting in reduced effectiveness, impaired mitochondrial turnover, and altered redox homeostasis [78,81]. Thus, senescent muscle cells present significant morphological and functional changes when evaluated [82]. Therefore, mitochondrial integrity loss is considered a factor associated with muscle impairment (Figure 1). The need for therapeutic strategies that intervene in this metabolic process—specifically, mitochondrial quality-control mechanisms such as mitochondrial dynamics and mitophagy—is crucial for maintaining metabolic balance and mitochondrial health in skeletal muscle [77,83]. The interaction of mitochondrial dysfunction with other systemic processes, such as inflammation, hormonal decline, and intestinal dysbiosis, may further amplify the pathophysiological cycle underlying sarcopenia and its neurological consequences [84–88]. These interconnected mechanisms are illustrated in Figure 2, which integrates the inflammation–mitochondria–muscle axis with gut and neural pathways involved in aging-related functional decline.



**Figure 1.** Inflammation-Mitochondria-Muscle Axis. Chronic inflammation in the elderly, mediated by pro-inflammatory cytokines such as TNF- $\alpha$ , IL-6, and IL-1 $\beta$ , leads to mitochondrial dysfunction and increased ROS production, causing oxidative stress, mtDNA damage, and UPS activation. This process can lead to protein degradation, reduced biogenesis, and impaired energy production, ultimately culminating in the muscle atrophy typical of sarcopenia. This vicious cycle perpetuates inflammation and exacerbates the loss of muscle function and mass. Vicious cycle: muscle atrophy releases pro-inflammatory myokines, fueling inflammation. IL: Interleukin; TNF- $\alpha$ : Tumor Necrosis Factor Alpha; UPS: Ubiquitin-Proteasome System; mtDNA: Mitochondrial DNA; ROS: Reactive Oxygen Species. Created in BioRender (<https://BioRender.com/zww4a7z>), last accessed on 3 December 2025.



**Figure 2.** Integrated Interaction of Axes in Sarcopenia and Neurodegeneration. Aging promotes systemic inflammation and hormonal decline, leading to mitochondrial dysfunction, which in turn results in oxidative stress and muscle atrophy. Coexisting intestinal dysbiosis contributes to reduced SCFAs and increased intestinal permeability, feeding back into the inflammatory state. The resulting muscle atrophy reduces myokine production, which in turn causes neurodegeneration and a decline in physical activity, perpetuating the cycle of functional deterioration. SCFAs: Short Chain Fatty Acids. Created in BioRender (<https://BioRender.com/v0emai0>), last accessed on 3 December 2025.

Table 1 summarizes the key factors associated with sarcopenia, and Table 2 presents promising biomarkers for therapeutic approaches to sarcopenia.

Collectively, these mechanisms can be conceptualized as components of a unified systemic inflammation–oxidative stress–energy metabolism axis. Chronic low-grade inflammation acts as the initiating event, promoting the release of pro-inflammatory cytokines (e.g.,  $\text{TNF-}\alpha$ , IL-6, IL-1 $\beta$ ) that activate intracellular signaling cascades leading to mitochondrial dysfunction and excessive ROS production. The resulting oxidative stress further amplifies inflammatory signaling, disrupts mitochondrial biogenesis, and impairs energy metabolism, ultimately leading to impaired muscle protein turnover and anabolic resistance. Thus, inflammation, oxidative stress, and mitochondrial dysfunction form a self-perpetuating feedback loop that drives the progression of sarcopenia. This hierarchical interplay is illustrated in Figure 1, which integrates these mechanisms into a coherent pathophysiological framework.

**Table 1.** Main Pathophysiological Factors of Sarcopenia.

Mechanism	Key Processes	Impact on the Muscle	References
Chronic inflammation	- $\uparrow$ TNF- $\alpha$ , IL-6, IL-1 $\beta$ ; - NLRP3 inflammasome activation; - Pyroptosis.	- Proteolysis via UPS; - Anabolic resistance; - Fatty infiltration.	[89–91]
Oxidative Stress	- ROS accumulation; - Mitochondrial DNA damage; - $\downarrow$ Catalase/GSH activity.	- Type II fiber atrophy; - Satellite cell dysfunction; - Impaired regeneration.	[60–64]
Mitochondrial Dysfunction	- Impaired fusion/fission; - Mitophagy failure; - $\downarrow$ Biogenesis.	- Energy deficit; - $\uparrow$ ROS production; - Muscle apoptosis.	[83,92,93]
Anabolic Resistance	- Insulin resistance; - $\downarrow$ IGF-1/GH; - Impaired amino acid response.	- $\downarrow$ Protein synthesis; - Hypercatabolism; - Lean mass loss.	[94–96]
Neurodegeneration	- Neuromuscular junction degeneration; - Motor unit loss.	- Muscle denervation; - Inactivity-induced atrophy.	[97–99]
Hormonal changes	- $\downarrow$ Testosterone; - $\downarrow$ Vitamin D; - $\uparrow$ Cortisol.	- Reduced strength; - $\downarrow$ Muscle fiber density.	[100–102]

$\uparrow$ : Increase;  $\downarrow$ : Decrease; DNA: Deoxyribonucleic acid; GH: Growth hormone; GSH: Reduced glutathione; IGF-1: Insulin-like growth factor one; IL-1 $\beta$ : Interleukin-1 $\beta$ ; IL-6: Interleukin-6; NLRP3: Nucleotide-binding domain, leucine-rich repeat pyrin domain-containing protein 3; ROS: Reactive oxygen species; TNF- $\alpha$ : Tumor necrosis factor alpha; UPS: Ubiquitin-proteasome system.

**Table 2.** Promising Biomarkers for the Therapeutic Approach of Sarcopenia.

Category	Biomarkers	Association with Sarcopenia	References
Inflammatory	- IL-6, TNF- $\alpha$ , CRP; - NLRP3.	- Correlated with loss of muscle mass and strength.	[37,38,48,103]
Oxidative	- Malondialdehyde; - 8-OHdG.	- Markers of accelerated muscle aging and damage.	[104–106]
Mitochondrial	- Cytochrome C oxidase; - mtDNA deletions.	- Indicators of energy failure and apoptosis.	[63,107,108]
Myokines	- Irisin; - Myostatin.	- Mediate muscle-brain crosstalk and regulate neuroprotection/atrophy.	[74,109]
Hormonal	- IGF-1; - 25(OH) Vitamin D.	- Low levels linked to reduced muscle mass/strength.	[110–113]
Gut dysbiosis	- SCFAs	- With aging, a decline in SCFA-producing gut microbiomes reduces SCFAs, which contribute to sarcopenia.	[114]

8-OHdG: 8-hydroxy-2-deoxyguanosine; CRP: C-Reactive Protein; IGF-1: Insulin-like growth factor one; IL-6: Interleukin-6; mtDNA: mitochondrial DNA; NLRP3: Nucleotide-binding domain, leucine-rich repeat pyrin domain-containing protein 3; SCFA: Short-chain fatty acid; TNF- $\alpha$ : Tumor necrosis factor alpha.

## 2.2. Associated Clinical Conditions

### Sarcopenia and Diabetes Mellitus

T2DM is a complex metabolic disease, among the most prevalent worldwide. With high morbidity and mortality rates, this condition affects approximately 25% of the population over 65 years. Affected individuals have a twice-increased risk of developing sarcopenia, with an increased functional impact resulting from this loss of muscle mass, which can be secondary to T2DM, a medical condition, or aging itself. Studies have shown that this interaction is due to the negative impact of muscle mass loss in malnourished elderly diabetic patients or even the risk of malnutrition [115–120].

Analyses have shown different mechanisms to explain the greater incidence of sarcopenia in the diabetic population. Hyperinsulinemia, present in each metabolic profile,

resulting from prolonged physiological increases, compromises insulin sensitivity. Consequently, the anabolic effect on skeletal muscle becomes increasingly imperceptible, leading to reduced protein synthesis and increased muscle degradation due to reduced insulin action, compromising muscle mass and strength. The catabolic state is also involved in this relationship through protein catabolism and muscle loss [115,121–124].

Furthermore, hyperglycemia is associated with several metabolic abnormalities that correlate with muscle damage and mitochondrial dysfunction, resulting in the accumulation of intramyocellular lipid metabolites. Chronic hyperglycemia promotes the accumulation of advanced glycation end products (AGEs) in skeletal muscle, and this relationship is associated with reduced grip strength, leg extension power, and slow walking speed [124–127].

Furthermore, diabetes is known to be intrinsically linked to increased levels of inflammatory cytokines, such as IL-6 and TNF- $\alpha$ , which contribute to muscle loss [128]. Thus, elevated levels of specific inflammatory markers are associated with decreased muscle strength and function. The protein catabolic pathway, already mentioned in this topic, can be triggered by the inflammatory cascade, leading to muscle atrophy, which in turn reduces both physical performance and functional capacity, highlighting the complexities faced by individuals with diabetes [126,129,130].

Recent evidence indicates that the relationship between sarcopenia and T2DM is bidirectional [131]. Not only does diabetes increase the risk of sarcopenia through hyperglycemia, insulin resistance, and chronic inflammation, but sarcopenia itself may exacerbate insulin resistance and impair glucose homeostasis [132]. Longitudinal studies have shown that reduced muscle mass is a predictor of diabetes development in patients with impaired glucose regulation [133]. Additionally, Mendelian randomization analyses suggest a potential causal role of sarcopenia-related traits in increasing the risk of diabetes, highlighting the complex interplay between muscle loss and metabolic dysfunction [134]. Therefore, interventions targeting muscle mass and function may have beneficial effects not only on physical performance but also on glycemic control and metabolic health.

In individuals who fit the profile of sarcopenia and T2DM, there is a concern about the reduction in bone mass (Figure 3), since it contributes to a greater risk of fractures due to bone fragility. This condition is more common in women, who are more susceptible to osteoporosis, which can end up reducing the mobility and quality of life of these people [135,136]. This increased susceptibility in women may be partly explained by hormonal changes, particularly the decline in estrogen levels after menopause, which accelerates bone resorption and contributes to both reduced bone density and loss of muscle mass [137]. Estrogen also plays a regulatory role in glucose metabolism and muscle protein turnover; thus, its deficiency can exacerbate the interplay between sarcopenia and diabetes [138]. Moreover, age-related hormonal decline in both sexes, along with reduced physical activity and nutritional intake in older adults, further increases vulnerability to muscle and bone deterioration [139].

Finally, it is known that there is a relationship between the presence of macrovascular and microvascular complications, that is, nephropathy, retinopathy, and neuropathy, in diabetic and sarcopenic individuals, which together can affect muscle mass, can lead to a reduction in physical activity, can induce muscle ischemia, decrease strength, muscle mass, and the individual's physical performance [115,140]. Therefore, it becomes essential to implement improvements to identify sarcopenia and its risk factors in patients with T2DM. Targeted therapies should promote adequate nutrition and regular physical exercise, especially resistance and aerobic exercise, to enhance muscle mass and strength, and improve physical performance in sarcopenia [141,142].



and chronic or acute pathologies, which together play a relevant role in the etiopathogenesis of sarcopenic obesity [155]. As pointed out above, several risk factors can lead to the development of sarcopenia, including excess alcohol consumption, smoking, physical inactivity, processed meats, and excess salt, which are linked to an increased risk of muscle loss [153]. These factors contribute to increased fat mass, decreased muscle mass, and reduced bone mass among the elderly, which can lead to obesity, sarcopenia, and osteoporosis [145].

In summary, individuals with sarcopenic obesity are known to have a higher prevalence of developing cardiovascular problems and metabolic syndrome [156], which are strongly associated with inflammatory markers. Studies show that hyperglycemia, insulin resistance, and excess cytokine production can contribute to sarcopenia, leading to reduced fiber diameter, metabolic degradation of skeletal muscle, and a more severe sarcopenic process [44,157]. Hence, it is worth emphasizing that a balanced diet and physical activity are essential as prophylactic treatments for sarcopenia and obesity, as they aim to reduce the onset of several risk factors for these pathologies, both individually and in combination. In addition, it is necessary to control conditions such as smoking, alcohol consumption, and a sedentary lifestyle [150,158–160].

### **Sarcopenia and Neurodegenerative Diseases**

Sarcopenia is associated with several adverse health consequences, including the risk of falls, fractures, physical disability, and increased mortality. However, beyond these factors, attention has focused on the relationship between sarcopenia and cognitive impairment, including Alzheimer's disease (AD). This prevalent degenerative brain disease is the leading cause of dementia worldwide and is associated with impaired cognitive function, which, like sarcopenia, tends to develop with aging. Studies have shown that patients with mild cognitive impairment (MCI), AD, and PD have a higher prevalence of sarcopenia, which can lead to worsening physical and cognitive health [161–164].

Even in the early stages of AD and throughout its progression, it is well established that physical performance, particularly gait, muscle strength, and balance, deteriorates [165,166]. Despite the evidence that sarcopenia is closely associated with cognitive impairment, there is currently no conclusive mechanism. Therefore, it is known that sarcopenia and AD share similarities, such as inflammation, oxidative stress, nutrition, immobility, and hormonal dysregulation. Inflammatory dysregulation can affect the central nervous system and contribute to the pathophysiological mechanisms of neurodegenerative diseases such as AD [167,168].


On the other hand, there is also a link between sarcopenia and PD, a neurodegenerative movement disorder characterized by the death of dopaminergic neurons. As the disease progresses, various symptoms emerge, including reduced motor skills, body changes, and decreased physical performance, which can affect the vitality of these patients. These same signs and symptoms have been observed in patients who develop sarcopenia after aging, demonstrating a strong link between aging and the interaction between sarcopenia and neurodegenerative diseases [31,169,170]. Studies have shown that the interaction between sarcopenia and PD is related to their common pathway, neuroinflammation, with elevated levels of inflammatory mediators detected in sarcopenic and PD patients. Furthermore, muscle loss and poor physical performance in PD patients have been associated with elevated levels of IL-6. Moreover, mild motor neuron degeneration is another mechanism of neurogenic sarcopenia in PD, with a low number of motor units observed in these patients. Sarcopenia can be influenced by hormonal changes, with androgens being essential for maintaining muscle mass. Low testosterone levels can also cause or accelerate age-related diseases such as sarcopenia [171–173].

It is well known that declines in cognitive and physical performance are common in old age. Geroscience, the scientific field responsible for the study of biological aging and the phenomena it triggers, has supported the association regarding the pathophysiology behind

physical functional decline, cognitive decline, and sarcopenia, which share physiological pathways and processes that culminate in these diseases [74,174–177].

Among the factors contributing to the development of these pathologies, particularly in the context of cognitive decline, are mitochondrial dysfunction, alterations in cellular organization, changes in endocellular signaling, inflammation, and metabolic shifts, all of which are also observed in muscular senescence [178]. Thus, the presence or absence of sarcopenia in the elderly may be a crucial factor in cognitive performance [179,180].

On the other hand, neurological factors are among the determinants of sarcopenia development, as neuromuscular junctions—synapses that connect the skeletal muscle system to the nervous system—play a crucial role in aging-related musculoskeletal disorders. Specific patterns of circulating metabolic and neurotrophic factors have been associated with the development of physical functional decline and sarcopenia. These factors are primarily linked to changes in the conversion of proteins into energy and an insufficient intake of calories and proteins necessary for maintaining muscle mass. Some studies have also described the association between sarcopenia and cognitive decline in the elderly, which is likely mediated by myokines, substances produced by muscles that participate in communication between the brain and skeletal striated tissue [74,109,181–184]. Figure 4 shows the relationship between sarcopenia and neurodegenerative diseases.



**Figure 4.** Shared pathological mechanisms linking sarcopenia, cognitive impairment, and Parkinson's disease. Systemic factors—including inflammation, oxidative stress, inadequate nutrition, immobility, and hormonal dysregulation—negatively affect both muscle mass and brain function. These processes interact with shared risk factors such as diabetes mellitus (DM), systemic arterial hypertension (SAH), and cerebrovascular diseases, contributing to the development of sarcopenia and cognitive impairment (including Alzheimer's disease [AD], Parkinson's disease [PD], and mild cognitive impairment [MCI]). In PD, progressive loss of dopaminergic neurons further exacerbates motor decline, worsening immobility and perpetuating the cycle of muscle loss. The figure illustrates how these interconnected mechanisms reinforce one another, highlighting the bidirectional relationship between neurodegeneration and sarcopenia. Created in BioRender (<https://BioRender.com/lqh84wu>), last accessed on 3 December 2025.

Furthermore, studies reveal that sarcopenia and cognitive decline share risk factors, such as diabetes, systemic arterial hypertension, and cerebrovascular diseases. Chronic inflammation resulting from immuno-senescence and increased cytokine release has been shown to have harmful effects. Elevated levels of IL-6, CRP, and TNF- $\alpha$  have been investigated as possible pathophysiological mechanisms involved in sarcopenia. Dysregulation of the inflammatory response may also contribute to the development of MCI. Furthermore, studies suggest that adopting a Mediterranean diet, combined with a high intake of quality proteins, may reduce the risk of MCI and sarcopenia. Consequently, the balance between muscle protein synthesis and degradation levels is an essential factor in the etiology of muscle atrophy in individuals with sarcopenia. Thus, inadequate nutritional intake may be one of the possible explanations for the association of the manifestation of MCI together with sarcopenia in the elderly; consequently, interventions in sarcopenia or cognitive decline may bring numerous long-term benefits to patients affected by these pathologies [185–189].

### **Sarcopenia and Aging**

Sarcopenia is associated with aging, as cellular senescence and subsequent metabolic changes lead to a progressive decline of skeletal muscle mass and function [190]. Thus, there is a rise in the prevalence of sarcopenia with advancing age. Elderly adults aged 70 and above experience a 20% loss of muscle mass [191]. However, this condition reflects the cumulative effects of a lifetime, influenced by lifestyle habits, physical exercise, and genetic factors, resulting in a decline in strength capacity in adult individuals from the age of 30 [192,193].

The reduction in anabolic components, such as growth hormone (GH) and insulin-like growth factor one (IGF-1), associated with the greater expression of catabolic substances that occurs with aging, compromises muscle homeostasis, thus reflecting a pathogenic pillar for sarcopenia [194,195]. Anabolic resistance is therefore established in the elderly as an attenuated response to physical and nutritional stimuli, leading to reduced muscle protein synthesis in the presence of naturally occurring hormonal dysregulation [196]. Furthermore, the subclinical inflammatory state in elderly individuals contributes to the establishment of the pathogenic process, as evidenced by elevated levels of inflammatory cytokines [197,198].

Due to the lower muscle index, affected individuals have a greater risk of fractures due to fragility, falls, cognitive disorders, and numerous geriatric syndromes, thus compromising individual autonomy [199]. Based on this, it is possible to conclude that the most effective management for sarcopenia is a multi-domain intervention that targets physical, cognitive, and nutritional health, aiming to increase the population's life expectancy [200,201]. It is also necessary to reduce the pro-inflammatory state in this population group through physical exercise, preferably resistance training, in combination with long-term nutritional support that emphasizes protein intake [202,203].

### *2.3. Gut Sarcopenia-Cognition Interaction*


Homeostasis is established through various mechanisms, including bidirectional communication between the brain and the intestinal microbiota, mediated by endocrine, neural, or immunological factors [204,205]. Therefore, it is considered that during aging, it is natural for transitions to happen in the composition of the intestinal microbiota due to changes in colonization patterns, which may, in turn, influence the inflammatory state, as well as the development of neural metabolic changes and age-related pathophysiological processes [206–208].

Dysbiosis, therefore, appears to be a key factor in the dysregulation of the brain–gut axis, resulting in impaired neurodevelopment, gastrointestinal disorders, and physiological changes in the inflammatory process of the central nervous system [209,210]. Thus, the activation of neuroinflammatory pathways, such as the NLRP3 inflammasome, is directly associated with the diagnosis of neurodegenerative pathologies, including AD, PD, and Multiple Sclerosis [211–213].

The gut–brain axis also affects skeletal muscles, forming the microbiota–gut–muscle axis [214,215]. This demonstrates the presence of a low-grade inflammatory state and anabolic resistance, due to changes in the composition of the intestinal microbiota, which may favor the development of muscular phenotypes such as sarcopenia in already frail elderly individuals, by compromising the availability of lean muscle mass and affecting the function of a specific cell group [216–218].

Recent studies have provided more profound insight into the mechanistic pathways linking gut dysbiosis to both sarcopenia and cognitive decline. A reduction in short-chain fatty acid (SCFA)–producing bacteria, particularly *Faecalibacterium prausnitzii* and *Roseburia* spp., leads to decreased levels of butyrate [219]. This key metabolite maintains intestinal barrier integrity and exerts anti-inflammatory and neuroprotective effects [220]. Loss of this metabolite increases intestinal permeability, facilitating the translocation of lipopolysaccharides (LPS) into the circulation, thereby activating Toll-like Receptor 4 (TLR4)/Nuclear Factor Kappa B (NF- $\kappa$ B) signaling and promoting inflammation [221,222]. This chronic inflammatory state not only triggers microglial activation and NLRP3 inflammasome assembly in the brain but also impairs skeletal muscle homeostasis by disrupting insulin–protein kinase B (Akt) signaling, impairing mitochondrial function, and enhancing proteolytic activity via the ubiquitin–proteasome and autophagy–lysosomal systems [86,223–226]. Additionally, alterations in the tryptophan–kynurenine pathway have been implicated in both neurodegenerative and sarcopenic processes [227]. Together, these mechanisms establish a shared inflammatory–metabolic network—the gut–muscle–brain axis—linking microbial imbalance to the dual decline in physical and cognitive function.

Therefore, the pro-inflammatory environment resulting from aging and the consequent disturbance of the intestinal microbiota are common conditions associated with the neuro- and muscular degenerative pathological process [228,229]. Thus, early physical and nutritional interventions, such as the Mediterranean diet, appear to be positively associated with improvements in the intestinal microbiota, due to greater SCFA synthesis and a consequent favorable prognosis for frailty and neurodegenerative conditions [230–232]. Figure 5 summarizes the relationship among dysbiosis, neurodegeneration, and muscle loss.



**Figure 5.** Interaction of sarcopenia with the gut–brain axis and gut–muscle axis. Dysbiosis of the intestinal microbiota triggers chronic and systemic inflammation, which affects both the brain (via the gut–brain axis) and the muscles (via the gut–muscle axis), accelerating the development/onset of sarcopenia and neurodegeneration. NLRP3: Nucleotide-binding domain, leucine-rich repeat pyrin domain-containing protein 3. Created in BioRender (<https://BioRender.com/ql0gnzg>), last accessed on 3 December 2025.

#### 2.4. Sarcopenia and Therapeutic Strategies

Therapies evaluated for preventing and treating sarcopenia have become widely studied, aiming to promote a better quality of life and reduce geriatric syndromes in the context of aging. Among the mechanisms considered for the treatment and prevention of sarcopenia in the elderly is dynamic resistance exercise (DRE), which, when performed at low volume/high intensity training (HIT) and combined with a protein diet, vitamin D, and calcium, proved to be significant in the scenario evaluated [233–236]. Analyses also show that high-intensity resistance training (HRT) is superior to low-load resistance exercise (LRT) for improving muscle mass, increasing muscle hypertrophy, and consequently improving the pathological state of sarcopenia. However, the high mechanical loads associated with its practice pose a barrier to its demand, leading to the search for safer approaches for vulnerable populations with greater degrees of physical disability, such as blood flow restriction (BFR) training [237].

Nutrition is a modifiable lifestyle factor in sarcopenia, which can be used to promote healthier, possibly more active aging, characterized by a continuous and gradual process of natural changes [238]. Given this, a higher protein intake is recommended to preserve muscle mass and physical fitness in old age, thereby improving physical performance and strength [238,239]. This indication is based on the fact that the muscle requires a greater quantity of amino acids to achieve maximum stimulation of protein synthesis with age, which is mainly driven by hyperaminoacidemia [238,240,241].

Failure to properly stimulate muscle protein synthesis leads to a gradual loss of muscle mass, particularly in type II fibers, which compromises muscle strength and the individual's physical condition. However, studies have shown that the increase in type II fibers can be stimulated by physical exercise, especially resistance exercise, thereby reversing the decline in satellite cells associated with sarcopenia [242,243]. Some authors have also demonstrated that older adults with lower protein intake are more susceptible to sarcopenia than those with a protein-based diet. Furthermore, consumption of plant-based protein was associated with a lower prevalence of the disease. At the same time, older adults who consume a high-fat diet are at a higher risk, even if their protein intake is higher. It has been widely discussed that adequate protein intake can help prevent the development of sarcopenia or at least its progression, but the findings are still inconclusive [238,244,245].

The relationship between diet and maintaining muscle mass for healthy aging is currently a widely discussed topic. It has attracted the attention of researchers, particularly regarding the effects of essential nutrients, such as amino acids, vitamins, omega-3 fatty acids, and calcium, in preventing and even delaying the progression of sarcopenia when consumed in appropriate amounts and forms [246,247]. Proteins from whey have demonstrated an essential role in anabolic stimulation due to their faster digestion, resulting in a slight increase in plasma amino acid levels, in addition to the high content of essential amino acids, including leucine, which stimulates anabolism autonomously, thus demonstrating their role in reducing the risk of developing sarcopenia [248,249].


Furthermore, vitamin D supplementation has been found to improve muscle strength, particularly in elderly individuals with low serum vitamin D levels [248,250]. Studies have shown that vitamin D is essential for skeletal muscle health. It affects skeletal muscle function by regulating calcium and phosphorus metabolism, promoting muscle protein synthesis, and modulating cell proliferation and differentiation. Since this vitamin exerts synergistic effects on the protein anabolic mechanism, its deficiency is a risk factor for the development of sarcopenia. Furthermore, the combination of milk protein, leucine, and vitamin D supplementation has been shown to increase muscle mass in patients with sarcopenia. Furthermore, physical exercise combined with supplementation can improve fitness, function, and muscle gain [251–255].

Given these issues, the frequent consumption of ultra-processed foods increases the risk of developing sarcopenia or even precedes its onset. Processed foods often promote lower intake of nutrients, including protein, dietary fiber, vitamins A, C, and E, zinc, selenium, magnesium, and iron. Thus, obesity caused by this diet promotes muscle loss. Besides being low in antioxidants, it increases the risk of inflammation and sarcopenia [256,257]. Therefore, it is necessary to raise awareness of eating habits to reduce consumption of ultra-processed foods, especially among the older population, and thereby mitigate the development of sarcopenia [258].

Furthermore, leucine administration has been considered for the treatment of sarcopenia in the elderly, proving effective in its isolated form and as a co-supplement. In its isolated form, efficacy was demonstrated, as this amino acid was more efficient in stimulating muscle synthesis and reducing turnover. On the other hand, it was observed that when leucine is administered as a co-supplement with vitamin D, medium-chain triglycerides, and whey protein, it provides greater benefit for muscle strength. When combined, physical activity increases lean mass and strength and enhances the well-being of sarcopenic elderly individuals, compared to its isolated form [259–264]. Dietary interventions, such as amino acid supplementation, such as leucine, omega-3 fatty acids, and the probiotic *Lactobacillus*, also show significant therapeutic effects in reducing the progression of sarcopenia, acting on the physiology of muscle metabolism, regulating the turnover of muscle proteins, in addition to modulating the intestinal microbiota through its action on the muscle-intestinal axis [263,265,266].

Metabolic regulators, such as Bimagrumab<sup>®</sup>, are advancing in studies and remain promising in the evaluated scenario [267]. The monoclonal antibody targets activin type II receptors (ActRII), thereby regulating muscle metabolic pathways by inhibiting myostatin and other regulators of skeletal muscle mass [268–270]. Although selective androgen receptor modulators (SARMs) and myostatin inhibitors have been explored as potential therapeutic approaches for sarcopenia, clinical evidence remains inconsistent across randomized controlled trials, and neither agent has received regulatory approval. Therefore, these interventions are currently considered experimental and are not recommended for routine clinical use.

Among possible dietary supplements capable of modifying muscle status, the combination of hydroxymethylbutyrate, carnosine, magnesium, butyrate, and lactoferrin is also promising for treating sarcopenia, based on its effects on intestinal regulation, antioxidant effects, and direct positive action on muscle function. Thus, in validated studies, reductions in inflammatory markers were observed, along with an increase in muscle percentage in previously evaluated individuals [271–274]. Finally, multifactorial intervention is considered essential for the treatment and prevention of sarcopenia. Physical and behavioral modifications, combined with dietary supplementation, an anti-inflammatory diet, probiotics, and a protein diet, are fundamental pillars for improved muscle metabolism. Their outcomes are also being studied and evaluated in different combinations [275,276]. Figure 6 and Table 3 summarize the possible therapeutic approaches for sarcopenia.



**Figure 6.** Therapies for sarcopenia. Four pillars aim to improve muscle mass and quality of life in sarcopenic patients: exercise (e.g., HIT/RT), nutrition (e.g., protein and micronutrients), specific supplementation (e.g., HMB and probiotics), and pharmacotherapy. All of these methods work together to enhance protein synthesis, improve muscle function, and reduce muscle loss, ultimately improving the quality of life for these individuals. HIT/RT: high-intensity resistance training; HMB: hydroxymethylbutyrate. Created in BioRender (<https://BioRender.com/hw9w715>), last accessed on 3 December 2025.

**Table 3.** Evidence-Based Interventions.

Intervention	Strategies	Evidence-Based Outcomes	References
Physical exercise	- Resistance training; - Moderate aerobic exercise.	- ↑ Muscle mass; - ↑ Strength.	[277–279]
Protein Supplementation	- 1.2–1.5 g/kg/day protein; - Leucine-rich sources (whey).	- ↑ Gait speed.	[280]
Vitamin D	- Supplementation (800 IU).	- ↑ Appendicular muscle mass.	[281]
Mediterranean diet	- Omega-3, MUFA, and fiber.	- ↓ Systemic inflammation; - Bone-muscular protection.	[282,283]
Gut Microbiota Modulation	- Probiotics (e.g., <i>Lactobacillus</i> ); - Prebiotics.	- ↓ Muscle atrophy.	[265,266]
Multimodal Combination	- Exercise + protein + vitamin D.	- Synergistic effects (↑ muscle mass).	[263]

↑: Increase; ↓: Decrease; MUFA: Monounsaturated fatty acid.

### 3. Conclusions

Given the numerous mechanisms that contribute to sarcopenia in aging, further research is needed to elucidate its underlying mechanisms and pathological processes, and to identify effective treatments and preventive measures for clinical practice. Several pathophysiological mechanisms can cause sarcopenia. Despite the inconclusive findings,

its association with inflammatory pathways, mitochondrial dysfunction, and oxidative stress is evident. Elevated levels of inflammatory cytokines, such as IL-6, TNF- $\alpha$ , and CRP, were also observed in comorbidities related to the development of sarcopenia, such as T2DM, obesity, mitochondrial dysfunction, and metabolic alterations, confirming the current state of occurrence in the scenario evaluated, in addition to establishing common pathways for its pathological origin. Thus, unique comorbidities, such as T2DM and AD, were shown to be associated, underscoring the need to consider shared pathological biomarkers. Furthermore, the gut–brain–muscle axis was evaluated for its influence on skeletal muscle, revealing a low-grade inflammatory state and anabolic resistance, driven by changes in the gut microbiota composition. Consequently, physical and nutritional interventions, such as the Mediterranean diet, have been shown to positively impact the intestinal environment, highlighting the need for further studies on specific probiotics and microbiota-modulating diets to establish their effectiveness in clinical practice. Furthermore, studies demonstrate the prevention of sarcopenia through regular exercise and a healthy diet. Regarding the treatment of the evaluated condition, exposure to leucine alone or in combination with vitamin D and whey protein is significantly adequate. However, clinical guidelines and therapeutic plans remain inconclusive in the medical community. Finally, promising strategies for addressing the prospects of sarcopenia include amino acid supplementation, such as leucine, omega-3 fatty acids, and the probiotic *Lactobacillus*, as well as the monoclonal antibody Bimagrumab<sup>®</sup>, which has demonstrated effects in reducing muscle loss through various mechanisms.

While this review provides a comprehensive synthesis of current literature on the interactions among gut microbiota, sarcopenia, and cognition, several limitations should be acknowledged. First, our study is a narrative review rather than a formal meta-analysis, and we did not conduct a systematic critical appraisal of study quality, which may influence the robustness of the conclusions. Second, the selection of included studies may be subject to publication bias, as negative or null findings are less likely to be published. Third, much of the existing literature is derived from Western populations, which may limit the generalizability of our findings to other ethnic or geographical groups. Finally, many mechanistic pathways discussed remain based on preclinical or associative data, highlighting the need for further experimental and longitudinal human studies to confirm causal relationships. Despite these limitations, we believe that this review provides a valuable framework for understanding the gut–muscle–brain axis and identifies key avenues for future research.

#### 4. Future Perspectives

Given the relevance of sarcopenia and its multisystemic effects, such as cognitive decline, it is necessary to perform more studies aiming to clearly and directly demonstrate the mechanisms by which the onset of sarcopenia influences the development of various pathologies, including neurodegenerative diseases. These are also influenced by population aging itself and the most common pathologies in the elderly, such as T2DM and even obesity, all pathways linking sarcopenia to adverse health outcomes, particularly in populations with comorbidities such as cardiovascular disease, metabolic disorders, and chronic inflammation. Longitudinal studies with larger and more diverse cohorts are needed to establish predictive biomarkers and validate diagnostic criteria across different age groups and ethnicities. Furthermore, integrating multiomics approaches (genomics, proteomics, metabolomics) with advanced imaging techniques can provide deeper insights into muscle metabolism and its systemic interactions. The development and validation of targeted interventions combining nutritional strategies, physical activity protocols, and pharmacological agents should be prioritized, with a focus on individualized, precision-based medicine. Ultimately, collaborative, multidisciplinary efforts will be essential to

translate mechanistic discoveries into effective public health strategies for the prevention and treatment of sarcopenia.

**Author Contributions:** Conceptualization, L.P.A., A.C.F.G., F.F.F. and S.M.B.; investigation, L.P.A., A.C.F.G., F.F.F. and S.M.B.; writing—original draft preparation, L.P.A., A.C.F.G., F.F.F., C.B.L., K.Q., C.R.P.D., A.C.A., M.A.M., E.L.G., R.S.d.A.H., E.d.S.B.M.P., V.C.S.C. (Virgínia Cavallari Strozze Catharin), V.C.S.C. (Vitor Cavallari Strozze Catharin), L.F.L. and S.M.B.; writing—review and editing, L.P.A., A.C.F.G., F.F.F., C.B.L., K.Q., C.R.P.D., A.C.A., M.A.M., E.L.G., R.S.d.A.H., E.d.S.B.M.P., V.C.S.C. (Virgínia Cavallari Strozze Catharin), V.C.S.C. (Vitor Cavallari Strozze Catharin), L.F.L. and S.M.B.; visualization, L.P.A., A.C.F.G., F.F.F. and S.M.B.; supervision, S.M.B.; project administration, S.M.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** No new data were created or analyzed in this study. Data sharing does not apply to this article.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## Appendix A

### *Study Design*

This work was conducted as an integrative literature review to synthesize recent evidence on the cellular mechanisms, clinical associations, and therapeutic strategies related to sarcopenia and its risk factors.

### *Search Strategy*

A comprehensive search was conducted in the PubMed, Scopus, Web of Science, and ScienceDirect databases for relevant studies. We did not restrict the search period. Additional sources were identified through Google Scholar and manual review of references. The search combined terms such as “sarcopenia,” “muscle atrophy,” “oxidative stress,” “inflammation,” “mitochondrial dysfunction,” “aging,” “diabetes,” “obesity,” “neurodegeneration,” “microbiota,” “therapy,” “exercise,” and “nutrition.”

### *Eligibility Criteria*

Studies were included if they examined sarcopenia or muscle atrophy in adult or elderly populations and explored molecular, cellular, or clinical mechanisms, or evaluated preventive and therapeutic interventions. Case reports, abstracts, and non-peer-reviewed sources were excluded.

### *Data Extraction and Synthesis*

Data were extracted and organized into thematic domains: (1) cellular and molecular mechanisms, (2) associated clinical conditions, (3) gut–muscle–brain interactions, and (4) therapeutic strategies. Figures were prepared using BioRender (<https://BioRender.com>, last accessed on 3 December 2025).

## References

1. Mao, X.; Lv, K.; Qi, W.; Cheng, W.; Li, T.; Sun, Y.; Jin, H.; Pan, H.; Wang, D. Research progress on sarcopenia in the musculoskeletal system. *Bone Res.* **2025**, *13*, 78. [[CrossRef](#)]
2. Jung, H.; Tanaka, S.; Kataoka, S.; Tanaka, R. Association of sarcopenia, pre-sarcopenia, and dynapenia with the onset and progression of locomotive syndrome in Japanese older adults: A cross-sectional study. *J. Physiol. Anthropol.* **2023**, *42*, 16. [[CrossRef](#)] [[PubMed](#)]

3. Liu, J.; Zhang, F. Associations between sarcopenia (defined by low muscle mass), inflammatory markers, and all-cause mortality in older adults: Mediation analyses in a large U.S. NHANES community sample, 1999–2006. *Front. Med.* **2025**, *12*, 1515839. [[CrossRef](#)] [[PubMed](#)]
4. Huang, J.; Li, M.; Luo, Q.; Li, J. The association of sarcopenia, possible sarcopenia and cognitive impairment: A systematic review and meta-analysis. *PLoS ONE* **2025**, *20*, e0324258. [[CrossRef](#)]
5. Wang, T.; Zhou, D.; Hong, Z. Sarcopenia and cachexia: Molecular mechanisms and therapeutic interventions. *MedComm* **2025**, *6*, e70030. [[CrossRef](#)] [[PubMed](#)]
6. Alorfi, N.M.; Alshehri, F.S.; Ashour, A.M. Therapeutics for Sarcopenia and Functional Disabilities in Older Adults: A Review of Phase 4 Clinical Trials. *Drug Des. Dev. Ther.* **2025**, *19*, 2307–2314. [[CrossRef](#)]
7. Laurindo, L.F.; Rodrigues, V.D.; Laurindo, L.F.; Cherain, L.M.A.; de Lima, E.P.; Boaro, B.L.; da Silva Camarinha Oliveira, J.; Chagas, E.F.B.; Catharin, V.C.S.; Dos Santos Haber, J.F.; et al. Targeting AMPK with Irisin: Implications for metabolic disorders, cardiovascular health, and inflammatory conditions—A systematic review. *Life Sci.* **2025**, *360*, 123230. [[CrossRef](#)]
8. Nunes-Pinto, M.; Bandeira de Mello, R.G.; Pinto, M.N.; Moro, C.; Vellas, B.; Martinez, L.O.; Rolland, Y.; de Souto Barreto, P. Sarcopenia and the biological determinants of aging: A narrative review from a geroscience perspective. *Ageing Res. Rev.* **2025**, *103*, 102587. [[CrossRef](#)]
9. Wang, N.; Zheng, A.; Yan, Y.; He, T.; Wu, X.; Xian, M.; Luo, J.; Li, C.; Wei, J.; Wang, Y.; et al. Aging induces sarcopenia by disrupting the crosstalk between the skeletal muscle microenvironment and myofibers. *J. Adv. Res.* **2025**. [[CrossRef](#)]
10. Ceccarelli Ceccarelli, D.; Solerte, S.B. Unravelling Shared Pathways Linking Metabolic Syndrome, Mild Cognitive Impairment, Dementia, and Sarcopenia. *Metabolites* **2025**, *15*, 159. [[CrossRef](#)]
11. Burks, T.N.; Cohn, R.D. Role of TGF- $\beta$  signaling in inherited and acquired myopathies. *Skelet. Muscle* **2011**, *1*, 19. [[CrossRef](#)]
12. Shirakawa, T.; Toyono, T.; Inoue, A.; Matsubara, T.; Kawamoto, T.; Kokabu, S. Factors Regulating or Regulated by Myogenic Regulatory Factors in Skeletal Muscle Stem Cells. *Cells* **2022**, *11*, 1493. [[CrossRef](#)] [[PubMed](#)]
13. Habboub, B.; Speer, R.; Gosch, M.; Singler, K. The Diagnosis and Treatment of Sarcopenia and Sarcopenic Obesity. *Dtsch. Arztebl. Int.* **2025**, *122*, 121–126. [[CrossRef](#)]
14. Yogesh, M.; Patel, M.; Gandhi, R.; Patel, A.; Kidecha, K.N. Sarcopenia in type 2 Diabetes mellitus among Asian populations: Prevalence and risk factors based on AWGS- 2019: A systematic review and meta-analysis. *BMC Endocr. Disord.* **2025**, *25*, 101. [[CrossRef](#)] [[PubMed](#)]
15. Xie, R.Z.; Li, X.S.; Zha, F.D.; Li, G.Q.; Zhao, W.Q.; Liang, Y.F.; Huang, J.F. Relationship Between Body Mass Index and Low Skeletal Muscle Mass in Adults Based on NHANES 2011–2018. *Sci. Rep.* **2025**, *15*, 2596. [[CrossRef](#)] [[PubMed](#)]
16. Aguiar, M.B.; Kim, S.; Bortoluzzo, A.B.; Di Tommaso, A.B.; Cendoroglo, M.S.; Colleoni, G.W.B. Sarcopenia in independent oldest-old individuals treated for diabetes, with or without metformin: A case-control study. *Acta Diabetol.* **2025**, *62*, 1271–1281. [[CrossRef](#)]
17. Wang, X.; Bai, Y.; Zhang, F.; Que, H. Association of sarcopenia index, based on serum creatinine and cystatin C, with incident diabetes mellitus. *Eur. J. Med. Res.* **2025**, *30*, 151. [[CrossRef](#)]
18. Elnaggar, R.K.; Mahmoud, W.S.; Abdrabo, M.S.; Elfakharany, M.S. Effect of adaptive variable-resistance training on chemotherapy-induced sarcopenia, fatigue, and functional restriction in pediatric survivors of acute lymphoblastic leukemia: A prospective randomized controlled trial. *Support. Care Cancer* **2025**, *33*, 214. [[CrossRef](#)]
19. Lee, M.C.; Hsu, Y.J.; Yang, H.J.; Huang, C.C. Enhancement of Lower Limb Muscle Strength and Reduction of Inflammation in the Elderly: A Randomized, Double-Blind Clinical Trial Comparing. *Nutrients* **2025**, *17*, 463. [[CrossRef](#)]
20. Hämäläinen, O.O.; Savikangas, T.M.; Tirkkonen, A.K.; Alén, M.J.; Hautala, A.J.; Sipilä, S. Effects of 12-month physical and cognitive training on sarcopenia determinants in older adults: A subgroup analysis of a randomised clinical trial. *Ageing Clin. Exp. Res.* **2025**, *37*, 36. [[CrossRef](#)]
21. Urban, R.J.; Dillon, E.L.; Choudhary, S.; Zhao, Y.; Horstman, A.M.; Tilton, R.G.; Sheffield-Moore, M. Translational studies in older men using testosterone to treat sarcopenia. *Trans. Am. Clin. Climatol. Assoc.* **2014**, *125*, 27–42; discussion 42–44.
22. Atkinson, R.A.; Srinivas-Shankar, U.; Roberts, S.A.; Connolly, M.J.; Adams, J.E.; Oldham, J.A.; Wu, F.C.; Seynnes, O.R.; Stewart, C.E.; Maganaris, C.N.; et al. Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. *J. Gerontol. A Biol. Sci. Med. Sci.* **2010**, *65*, 1215–1219. [[CrossRef](#)]
23. O’Connell, M.D.; Ravindrarajah, R.; Tajar, A.; Wu, F.C. Low testosterone in ageing men: A modifiable risk factor for frailty? *Trends Endocrinol. Metab.* **2011**, *22*, 491–498. [[CrossRef](#)]
24. Wittert, G.A.; Chapman, I.M.; Haren, M.T.; Mackintosh, S.; Coates, P.; Morley, J.E. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. *J. Gerontol. A Biol. Sci. Med. Sci.* **2003**, *58*, 618–625. [[CrossRef](#)]
25. Sha, T.; Zhang, Y.; Wei, J.; Li, C.; Zeng, C.; Lei, G.; Wang, Y. Sarcopenia and Risk of Cognitive Impairment: Cohort Study and Mendelian Randomization Analysis. *JMIR Aging* **2025**, *8*, e66031. [[CrossRef](#)] [[PubMed](#)]

26. Moradell, A.; Casajús, J.A.; Moreno, L.A.; Vicente-Rodríguez, G. Perspectives on Diet and Exercise Interaction for Healthy Aging: Opportunities to Reduce Malnutrition Risk and Optimize Fitness. *Nutrients* **2025**, *17*, 596. [[CrossRef](#)] [[PubMed](#)]
27. German, I.J.S.; Pomini, K.T.; Andreo, J.C.; Shindo, J.; Castro, M.V.M.; Detregiachi, C.R.P.; Araújo, A.C.; Guiguer, E.L.; Fornari Laurindo, L.; Bueno, P.; et al. New Trends to Treat Muscular Atrophy: A Systematic Review of Epicatechin. *Nutrients* **2024**, *16*, 326. [[CrossRef](#)]
28. Lipoeto, N.I.; Vanoh, D.; Desmawati, D.; Ishak, W.R.W.; Mohamed, R. Determinants of dementia risk among older adults with probable sarcopenia and sarcopenia. *BMC Public Health* **2025**, *25*, 1139. [[CrossRef](#)]
29. Zhan, Y.; Zhang, Z.; Lin, S.; Du, B.; Zhang, K.; Wu, J.; Xu, H. Causal association of sarcopenia-related traits with brain cortical structure: A bidirectional Mendelian randomization study. *Aging Clin. Exp. Res.* **2025**, *37*, 57. [[CrossRef](#)]
30. Shi, Y.; Zhang, Y.; Yang, X.; Yang, J.; Wang, S.; Hong, Y. The relationship between cognitive function and muscle mass in older adults: A longitudinal study based on CLHLS. *Front. Psychiatry* **2025**, *16*, 1595625. [[CrossRef](#)]
31. Wang, T.; Geng, J.; Zeng, X.; Han, R.; Huh, Y.E.; Peng, J. Exploring causal effects of sarcopenia on risk and progression of Parkinson disease by Mendelian randomization. *npj Park. Dis.* **2024**, *10*, 164. [[CrossRef](#)] [[PubMed](#)]
32. Peball, M.; Mahlkecht, P.; Werkmann, M.; Marini, K.; Murr, F.; Herzmann, H.; Stockner, H.; de Marzi, R.; Heim, B.; Djamshidian, A.; et al. Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. *Gerontology* **2019**, *65*, 216–228. [[CrossRef](#)]
33. Tan, A.H.; Hew, Y.C.; Lim, S.Y.; Ramli, N.M.; Kamaruzzaman, S.B.; Tan, M.P.; Grossmann, M.; Ang, B.H.; Tan, J.Y.; Manap, M.A.A.A.; et al. Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. *Park. Relat. Disord.* **2018**, *56*, 58–64. [[CrossRef](#)] [[PubMed](#)]
34. Ozer, F.F.; Akin, S.; Gultekin, M.; Zararsiz, G.E. Sarcopenia, dynapenia, and body composition in Parkinson's disease: Are they good predictors of disability? A case-control study. *Neurol. Sci.* **2020**, *41*, 313–320. [[CrossRef](#)] [[PubMed](#)]
35. de Lima, E.P.; Tanaka, M.; Lamas, C.B.; Quesada, K.; Detregiachi, C.R.P.; Araújo, A.C.; Guiguer, E.L.; Catharin, V.; de Castro, M.V.M.; Junior, E.B.; et al. Vascular Impairment, Muscle Atrophy, and Cognitive Decline: Critical Age-Related Conditions. *Biomedicines* **2024**, *12*, 2096. [[CrossRef](#)]
36. Zeng, Q.Y.; Qin, Y.; Shi, Y.; Mu, X.Y.; Huang, S.J.; Yang, Y.H.; Liu, S.M.; An, Z.M.; Li, S.Q. Systemic immune-inflammation index and all-cause and cause-specific mortality in sarcopenia: A study from National Health and Nutrition Examination Survey 1999–2018. *Front. Immunol.* **2024**, *15*, 1376544. [[CrossRef](#)]
37. Xu, W.; Mu, D.; Wang, Y.; Wang, C.; Zhang, X. Association between oxidative balance score and sarcopenia in US adults: NHANES 2011–2018. *Front. Nutr.* **2024**, *11*, 1342113. [[CrossRef](#)]
38. Hernández-Álvarez, D.; Rosado-Pérez, J.; Gavia-García, G.; Arista-Ugalde, T.L.; Aguiñiga-Sánchez, I.; Santiago-Osorio, E.; Mendoza-Núñez, V.M. Aging, Physical Exercise, Telomeres, and Sarcopenia: A Narrative Review. *Biomedicines* **2023**, *11*, 598. [[CrossRef](#)]
39. Chen, M.; Wang, Y.; Deng, S.; Lian, Z.; Yu, K. Skeletal muscle oxidative stress and inflammation in aging: Focus on antioxidant and anti-inflammatory therapy. *Front. Cell Dev. Biol.* **2022**, *10*, 964130. [[CrossRef](#)]
40. Franceschi, C.; Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J. Gerontol. A Biol. Sci. Med. Sci.* **2014**, *69*, S4–S9. [[CrossRef](#)]
41. Zembron-Lacny, A.; Dziubek, W.; Wolny-Rokicka, E.; Dabrowska, G.; Wozniowski, M. The Relation of Inflammaging with Skeletal Muscle Properties in Elderly Men. *Am. J. Mens Health* **2019**, *13*, 1557988319841934. [[CrossRef](#)]
42. Li, X.; Wu, C.; Lu, X.; Wang, L. Predictive models of sarcopenia based on inflammation and pyroptosis-related genes. *Front. Genet.* **2024**, *15*, 1491577. [[CrossRef](#)]
43. Beyer, I.; Mets, T.; Bautmans, I. Chronic low-grade inflammation and age-related sarcopenia. *Curr. Opin. Clin. Nutr. Metab. Care* **2012**, *15*, 12–22. [[CrossRef](#)] [[PubMed](#)]
44. Fielding, R.A.; Rolland, Y.; Bruyere, O.; Desvarieux, M.; Donini, L.M.; Incalzi, R.A.; Muscaritoli, M.; Tchalla, A.; Bonnefoy, M.; Rondanelli, M.; et al. Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: A multicenter observational trial (SARA-OBS). *BMC Geriatr.* **2025**, *25*, 590. [[CrossRef](#)] [[PubMed](#)]
45. Laurindo, L.F.; Lima, E.P.; Araújo, A.C.; Dogani Rodrigues, V.; Dias, J.A.; Barbosa Tavares Filho, M.; Zuccari, D.; Fornari Laurindo, L.; Miglino, M.A.; Chagas, E.F.B.; et al. Targeting Muscle Regeneration with Small Extracellular Vesicles from Adipose Tissue-Derived Stem Cells-A Review. *Cells* **2025**, *14*, 683. [[CrossRef](#)]
46. You, Z.; Huang, X.; Xiang, Y.; Dai, J.; Xu, L.; Jiang, J.; Xu, J. Ablation of NLRP3 inflammasome attenuates muscle atrophy via inhibiting pyroptosis, proteolysis and apoptosis following denervation. *Theranostics* **2023**, *13*, 374–390. [[CrossRef](#)]
47. Picca, A.; Calvani, R. Molecular Mechanism and Pathogenesis of Sarcopenia: An Overview. *Int. J. Mol. Sci.* **2021**, *22*, 3032. [[CrossRef](#)]
48. Merchant, R.A.; Chan, Y.H.; Anbarasan, D.; Vellas, B. Association of intrinsic capacity with functional ability, sarcopenia and systemic inflammation in pre-frail older adults. *Front. Med.* **2024**, *11*, 1374197. [[CrossRef](#)]

49. Arcaro, A.; Lepore, A.; Cetrangolo, G.P.; Paventi, G.; Ames, P.R.J.; Gentile, F. A Reassessment of Sarcopenia from a Redox Perspective as a Basis for Preventive and Therapeutic Interventions. *Int. J. Mol. Sci.* **2025**, *26*, 7787. [[CrossRef](#)]
50. Dhillon, R.J.; Hasni, S. Pathogenesis and Management of Sarcopenia. *Clin. Geriatr. Med.* **2017**, *33*, 17–26. [[CrossRef](#)]
51. Xie, S.; Wu, Q. Association between the systemic immune-inflammation index and sarcopenia: A systematic review and meta-analysis. *J. Orthop. Surg. Res.* **2024**, *19*, 314. [[CrossRef](#)] [[PubMed](#)]
52. Guo, B.; Liu, X.; Si, Q.; Zhang, D.; Li, M.; Li, X.; Zhao, Y.; Hu, F.; Zhang, M.; Liu, Y.; et al. Associations of CBC-Derived inflammatory indicators with sarcopenia and mortality in adults: Evidence from Nhanes 1999 ~ 2006. *BMC Geriatr.* **2024**, *24*, 432. [[CrossRef](#)] [[PubMed](#)]
53. Cleasby, M.E.; Jamieson, P.M.; Atherton, P.J. Insulin resistance and sarcopenia: Mechanistic links between common co-morbidities. *J. Endocrinol.* **2016**, *229*, R67–R81. [[CrossRef](#)] [[PubMed](#)]
54. Damanti, S.; Senini, E.; De Lorenzo, R.; Merolla, A.; Santoro, S.; Festorazzi, C.; Messina, M.; Vitali, G.; Sciorati, C.; Rovere-Querini, P. Acute Sarcopenia: Mechanisms and Management. *Nutrients* **2024**, *16*, 3428. [[CrossRef](#)]
55. Pascual-Fernández, J.; Fernández-Montero, A.; Córdova-Martínez, A.; Pastor, D.; Martínez-Rodríguez, A.; Roche, E. Sarcopenia: Molecular Pathways and Potential Targets for Intervention. *Int. J. Mol. Sci.* **2020**, *21*, 8844. [[CrossRef](#)]
56. Khor, S.C.; Abdul Karim, N.; Ngah, W.Z.; Yusof, Y.A.; Makpol, S. Vitamin E in sarcopenia: Current evidences on its role in prevention and treatment. *Oxid. Med. Cell. Longev.* **2014**, *2014*, 914853. [[CrossRef](#)]
57. Szczesny, B.; Olah, G.; Walker, D.K.; Volpi, E.; Rasmussen, B.B.; Szabo, C.; Mitra, S. Deficiency in repair of the mitochondrial genome sensitizes proliferating myoblasts to oxidative damage. *PLoS ONE* **2013**, *8*, e75201. [[CrossRef](#)]
58. Barbalho, S.M.; Flato, U.A.P.; Tofano, R.J.; Goulart, R.A.; Guiguer, E.L.; Detregiachi, C.R.P.; Buchaim, D.V.; Araújo, A.C.; Buchaim, R.L.; Reina, F.T.R.; et al. Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications. *Int. J. Mol. Sci.* **2020**, *21*, 3607. [[CrossRef](#)]
59. Bailey, D.M.; McEneny, J.; Mathieu-Costello, O.; Henry, R.R.; James, P.E.; McCord, J.M.; Pietri, S.; Young, I.S.; Richardson, R.S. Sedentary aging increases resting and exercise-induced intramuscular free radical formation. *J. Appl. Physiol.* **2010**, *109*, 449–456. [[CrossRef](#)]
60. Fanò, G.; Mecocci, P.; Vecchiet, J.; Belia, S.; Fulle, S.; Polidori, M.C.; Felzani, G.; Senin, U.; Vecchiet, L.; Beal, M.F. Age and sex influence on oxidative damage and functional status in human skeletal muscle. *J. Muscle Res. Cell Motil.* **2001**, *22*, 345–351. [[CrossRef](#)]
61. Fulle, S.; Di Donna, S.; Puglielli, C.; Pietrangelo, T.; Beccafico, S.; Bellomo, R.; Protasi, F.; Fanò, G. Age-dependent imbalance of the antioxidative system in human satellite cells. *Exp. Gerontol.* **2005**, *40*, 189–197. [[CrossRef](#)]
62. Powers, S.K.; Duarte, J.; Kavazis, A.N.; Talbert, E.E. Reactive oxygen species are signalling molecules for skeletal muscle adaptation. *Exp. Physiol.* **2010**, *95*, 1–9. [[CrossRef](#)] [[PubMed](#)]
63. Marzetti, E.; Calvani, R.; Cesari, M.; Buford, T.W.; Lorenzi, M.; Behnke, B.J.; Leeuwenburgh, C. Mitochondrial dysfunction and sarcopenia of aging: From signaling pathways to clinical trials. *Int. J. Biochem. Cell Biol.* **2013**, *45*, 2288–2301. [[CrossRef](#)] [[PubMed](#)]
64. Hamilton, M.L.; Van Remmen, H.; Drake, J.A.; Yang, H.; Guo, Z.M.; Kewitt, K.; Walter, C.A.; Richardson, A. Does oxidative damage to DNA increase with age? *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 10469–10474. [[CrossRef](#)]
65. Tian, X.; Lou, S.; Shi, R. From mitochondria to sarcopenia: Role of 17 $\beta$ -estradiol and testosterone. *Front. Endocrinol.* **2023**, *14*, 1156583. [[CrossRef](#)] [[PubMed](#)]
66. Vasilaki, A.; Mansouri, A.; Van Remmen, H.; van der Meulen, J.H.; Larkin, L.; Richardson, A.G.; McArdle, A.; Faulkner, J.A.; Jackson, M.J. Free radical generation by skeletal muscle of adult and old mice: Effect of contractile activity. *Aging Cell* **2006**, *5*, 109–117. [[CrossRef](#)]
67. Lanza, I.R.; Sreekumaran Nair, K. Regulation of skeletal muscle mitochondrial function: Genes to proteins. *Acta Physiol.* **2010**, *199*, 529–547. [[CrossRef](#)]
68. Archer, S.L. Mitochondrial dynamics—Mitochondrial fission and fusion in human diseases. *N. Engl. J. Med.* **2013**, *369*, 2236–2251. [[CrossRef](#)]
69. Wai, T.; Langer, T. Mitochondrial Dynamics and Metabolic Regulation. *Trends Endocrinol. Metab.* **2016**, *27*, 105–117. [[CrossRef](#)]
70. Hood, D.A.; Memme, J.M.; Oliveira, A.N.; Triolo, M. Maintenance of Skeletal Muscle Mitochondria in Health, Exercise, and Aging. *Annu. Rev. Physiol.* **2019**, *81*, 19–41. [[CrossRef](#)]
71. Bene, M.R.; Chung, T.; Fountain, W.A.; Rosales-Soto, G.; Hernández-Ochoa, E.; Antonescu, C.; Florea, L.; Jeong, S.J.; Le, A.; Xue, Q.L.; et al. Chronic activation of a key exercise signal transducer, CaMKII, drives skeletal muscle aging and sarcopenia. *bioRxiv* **2025**. [[CrossRef](#)] [[PubMed](#)]
72. Fan, J.; Wen, X.; Duan, X.; Zhu, X.; Bai, J.; Zhang, T. Mitochondrial quality control in exercise-mitigated muscular atrophy. *Mitochondrion* **2025**, *85*, 102074. [[CrossRef](#)] [[PubMed](#)]
73. Chen, X.; Ji, Y.; Liu, R.; Zhu, X.; Wang, K.; Yang, X.; Liu, B.; Gao, Z.; Huang, Y.; Shen, Y.; et al. Mitochondrial dysfunction: Roles in skeletal muscle atrophy. *J. Transl. Med.* **2023**, *21*, 503. [[CrossRef](#)]

74. Arosio, B.; Calvani, R.; Ferri, E.; Coelho-Junior, H.J.; Carandina, A.; Campanelli, F.; Ghiglieri, V.; Marzetti, E.; Picca, A. Sarcopenia and Cognitive Decline in Older Adults: Targeting the Muscle-Brain Axis. *Nutrients* **2023**, *15*, 1853. [[CrossRef](#)] [[PubMed](#)]
75. Divino, I.A.; da Vieira-da-Silva, A.L.; Esteca, M.V.; Tonon, R.P.; da Cruz, F.O.G.; Braga, R.R.; Ropelle, E.R.; Gandra, P.G.; Baptista, I.L. Absence of Parkin Results in Atrophy of Oxidative Myofibers and Modulation of AKT and MURF1 Signaling in Middle-Aged Male Mice. *Acta Physiol.* **2025**, *241*, e70082. [[CrossRef](#)]
76. Mantle, D.; Kozhevnikova, S.; Larsen, S. Coenzyme Q10 and Obesity: An Overview. *Antioxidants* **2025**, *14*, 871. [[CrossRef](#)]
77. Lei, Y.; Gan, M.; Qiu, Y.; Chen, Q.; Wang, X.; Liao, T.; Zhao, M.; Chen, L.; Zhang, S.; Zhao, Y.; et al. The role of mitochondrial dynamics and mitophagy in skeletal muscle atrophy: From molecular mechanisms to therapeutic insights. *Cell. Mol. Biol. Lett.* **2024**, *29*, 59. [[CrossRef](#)]
78. Kubat, G.B.; Bouhamida, E.; Ulger, O.; Turkel, I.; Pedriali, G.; Ramaccini, D.; Ekinici, O.; Ozerklig, B.; Atalay, O.; Patergnani, S.; et al. Mitochondrial dysfunction and skeletal muscle atrophy: Causes, mechanisms, and treatment strategies. *Mitochondrion* **2023**, *72*, 33–58. [[CrossRef](#)]
79. Abrigo, J.; Simon, F.; Cabrera, D.; Vilos, C.; Cabello-Verrugio, C. Mitochondrial Dysfunction in Skeletal Muscle Pathologies. *Curr. Protein Pept. Sci.* **2019**, *20*, 536–546. [[CrossRef](#)]
80. Faitg, J.; Reynaud, O.; Leduc-Gaudet, J.P.; Gouspillou, G. Skeletal muscle aging and mitochondrial dysfunction: An update. *Med. Sci.* **2017**, *33*, 955–962. [[CrossRef](#)]
81. Srivastava, S. The Mitochondrial Basis of Aging and Age-Related Disorders. *Genes* **2017**, *8*, 398. [[CrossRef](#)] [[PubMed](#)]
82. Ferri, E.; Marzetti, E.; Calvani, R.; Picca, A.; Cesari, M.; Arosio, B. Role of Age-Related Mitochondrial Dysfunction in Sarcopenia. *Int. J. Mol. Sci.* **2020**, *21*, 5236. [[CrossRef](#)]
83. Leduc-Gaudet, J.P.; Hussain, S.N.A.; Barreiro, E.; Gouspillou, G. Mitochondrial Dynamics and Mitophagy in Skeletal Muscle Health and Aging. *Int. J. Mol. Sci.* **2021**, *22*, 8179. [[CrossRef](#)] [[PubMed](#)]
84. Ceyhan, A.B.; Altay, O.; Zhang, C.; Temel, S.G.; Turkez, H.; Mardinoglu, A. Unravelling the Complexity of Sarcopenia Through a Systems Biology Approach. *Int. J. Mol. Sci.* **2025**, *26*, 8527. [[CrossRef](#)] [[PubMed](#)]
85. Yang, J.; Jiang, F.; Yang, M.; Chen, Z. Sarcopenia and nervous system disorders. *J. Neurol.* **2022**, *269*, 5787–5797. [[CrossRef](#)]
86. Huang, Y.; Wang, C.; Cui, H.; Sun, G.; Qi, X.; Yao, X. Mitochondrial dysfunction in age-related sarcopenia: Mechanistic insights, diagnostic advances, and therapeutic prospects. *Front. Cell Dev. Biol.* **2025**, *13*, 1590524. [[CrossRef](#)]
87. Jeong, I.; Cho, E.J.; Yook, J.S.; Choi, Y.; Park, D.H.; Kang, J.H.; Lee, S.H.; Seo, D.Y.; Jung, S.J.; Kwak, H.B. Mitochondrial Adaptations in Aging Skeletal Muscle: Implications for Resistance Exercise Training to Treat Sarcopenia. *Life* **2024**, *14*, 962. [[CrossRef](#)]
88. Yuan, X.; Ouedraogo, S.Y.; Jammeh, M.L.; Simbilyabo, L.; Jabang, J.N.; Jaw, M.; Darboe, A.; Tan, Y.; Bajinka, O. Can microbiota gut-brain axis reverse neurodegenerative disorders in human? *Ageing Res. Rev.* **2025**, *104*, 102664. [[CrossRef](#)]
89. Eggelbusch, M.; Shi, A.; Broeksma, B.C.; Vázquez-Cruz, M.; Soares, M.N.; de Wit, G.M.J.; Everts, B.; Jaspers, R.T.; Wüst, R.C.I. The NLRP3 inflammasome contributes to inflammation-induced morphological and metabolic alterations in skeletal muscle. *J. Cachexia Sarcopenia Muscle* **2022**, *13*, 3048–3061. [[CrossRef](#)]
90. Jimenez-Gutierrez, G.E.; Martínez-Gómez, L.E.; Martínez-Armenta, C.; Pineda, C.; Martínez-Nava, G.A.; Lopez-Reyes, A. Molecular Mechanisms of Inflammation in Sarcopenia: Diagnosis and Therapeutic Update. *Cells* **2022**, *11*, 2359. [[CrossRef](#)]
91. Jorquera, G.; Russell, J.; Monsalves-Álvarez, M.; Cruz, G.; Valladares-Ide, D.; Basualto-Alarcón, C.; Barrientos, G.; Estrada, M.; Llanos, P. NLRP3 Inflammasome: Potential Role in Obesity Related Low-Grade Inflammation and Insulin Resistance in Skeletal Muscle. *Int. J. Mol. Sci.* **2021**, *22*, 3254. [[CrossRef](#)]
92. Romanello, V. The Interplay between Mitochondrial Morphology and Myomitokines in Aging Sarcopenia. *Int. J. Mol. Sci.* **2020**, *22*, 91. [[CrossRef](#)]
93. Gouspillou, G.; Bourdel-Marchasson, I.; Rouland, R.; Calmettes, G.; Franconi, J.M.; Deschodt-Arsac, V.; Diollez, P. Alteration of mitochondrial oxidative phosphorylation in aged skeletal muscle involves modification of adenine nucleotide translocator. *Biochim. Biophys. Acta* **2010**, *1797*, 143–151. [[CrossRef](#)]
94. McKee, A.; Morley, J.E.; Matsumoto, A.M.; Vinik, A. Sarcopenia: An Endocrine Disorder? *Endocr. Pract.* **2017**, *23*, 1140–1149. [[CrossRef](#)] [[PubMed](#)]
95. Tezze, C.; Sandri, M.; Tessari, P. Anabolic Resistance in the Pathogenesis of Sarcopenia in the Elderly: Role of Nutrition and Exercise in Young and Old People. *Nutrients* **2023**, *15*, 4073. [[CrossRef](#)] [[PubMed](#)]
96. Ferrari, U.; Schmidmaier, R.; Jung, T.; Reincke, M.; Martini, S.; Schoser, B.; Bidlingmaier, M.; Drey, M. IGF-I/IGFBP3/ALS Deficiency in Sarcopenia: Low GHBP Suggests GH Resistance in a Subgroup of Geriatric Patients. *J. Clin. Endocrinol. Metab.* **2021**, *106*, e1698–e1707. [[CrossRef](#)] [[PubMed](#)]
97. Deschenes, M.R.; Flannery, R.; Hawbaker, A.; Patek, L.; Mifsud, M. Adaptive Remodeling of the Neuromuscular Junction with Aging. *Cells* **2022**, *11*, 1150. [[CrossRef](#)]
98. Chugh, D.; Iyer, C.C.; Wang, X.; Bobbili, P.; Rich, M.M.; Arnold, W.D. Neuromuscular junction transmission failure is a late phenotype in aging mice. *Neurobiol. Aging* **2020**, *86*, 182–190. [[CrossRef](#)]

99. Arnold, W.D.; Clark, B.C. Neuromuscular junction transmission failure in aging and sarcopenia: The nexus of the neurological and muscular systems. *Ageing Res. Rev.* **2023**, *89*, 101966. [[CrossRef](#)]
100. Hosoi, T.; Yakabe, M.; Hashimoto, S.; Akishita, M.; Ogawa, S. The roles of sex hormones in the pathophysiology of age-related sarcopenia and frailty. *Reprod. Med. Biol.* **2024**, *23*, e12569. [[CrossRef](#)]
101. Morley, J.E.; Malmstrom, T.K. Frailty, sarcopenia, and hormones. *Endocrinol. Metab. Clin. N. Am.* **2013**, *42*, 391–405. [[CrossRef](#)] [[PubMed](#)]
102. Conzade, R.; Grill, E.; Bischoff-Ferrari, H.A.; Ferrari, U.; Horsch, A.; Koenig, W.; Peters, A.; Thorand, B. Vitamin D in Relation to Incident Sarcopenia and Changes in Muscle Parameters Among Older Adults: The KORA-Age Study. *Calcif. Tissue Int.* **2019**, *105*, 173–182. [[CrossRef](#)] [[PubMed](#)]
103. Merchant, R.A.; Chan, Y.H.; Anbarasan, D.; Aprahamian, I. Association of Motoric Cognitive Risk Syndrome with Sarcopenia and Systemic Inflammation in Pre-Frail Older Adults. *Brain Sci.* **2023**, *13*, 936. [[CrossRef](#)]
104. Liguori, I.; Russo, G.; Curcio, F.; Bulli, G.; Aran, L.; Della-Morte, D.; Gargiulo, G.; Testa, G.; Cacciatore, F.; Bonaduce, D.; et al. Oxidative stress, aging, and diseases. *Clin. Interv. Aging* **2018**, *13*, 757–772. [[CrossRef](#)] [[PubMed](#)]
105. Powers, S.K.; Ji, L.L.; Kavazis, A.N.; Jackson, M.J. Reactive oxygen species: Impact on skeletal muscle. *Compr. Physiol.* **2011**, *1*, 941–969. [[CrossRef](#)]
106. Frijhoff, J.; Winyard, P.G.; Zarkovic, N.; Davies, S.S.; Stocker, R.; Cheng, D.; Knight, A.R.; Taylor, E.L.; Oettrich, J.; Ruskovska, T.; et al. Clinical Relevance of Biomarkers of Oxidative Stress. *Antioxid. Redox Signal.* **2015**, *23*, 1144–1170. [[CrossRef](#)]
107. Chandrasekaran, K.; Giordano, T.; Brady, D.R.; Stoll, J.; Martin, L.J.; Rapoport, S.I. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. *Brain Res. Mol. Brain Res.* **1994**, *24*, 336–340. [[CrossRef](#)]
108. Picca, A.; Lozanoska-Ochser, B.; Calvani, R.; Coelho-Júnior, H.J.; Leewenburgh, C.; Marzetti, E. Inflammatory, mitochondrial, and senescence-related markers: Underlying biological pathways of muscle aging and new therapeutic targets. *Exp. Gerontol.* **2023**, *178*, 112204. [[CrossRef](#)]
109. Scisciola, L.; Fontanella, R.A.; Surina; Cataldo, V.; Paolisso, G.; Barbieri, M. Sarcopenia and Cognitive Function: Role of Myokines in Muscle Brain Cross-Talk. *Life* **2021**, *11*, 173. [[CrossRef](#)]
110. Ascenzi, F.; Barberi, L.; Dobrowolny, G.; Villa Nova Bacurau, A.; Nicoletti, C.; Rizzuto, E.; Rosenthal, N.; Scicchitano, B.M.; Musarò, A. Effects of IGF-1 isoforms on muscle growth and sarcopenia. *Aging Cell* **2019**, *18*, e12954. [[CrossRef](#)]
111. Bian, A.; Ma, Y.; Zhou, X.; Guo, Y.; Wang, W.; Zhang, Y.; Wang, X. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. *BMC Musculoskelet. Disord.* **2020**, *21*, 214. [[CrossRef](#)]
112. Hosoyama, T.; Iida, H.; Kawai-Takaishi, M.; Watanabe, K. Vitamin D Inhibits Myogenic Cell Fusion and Expression of Fusogenic Genes. *Nutrients* **2020**, *12*, 2192. [[CrossRef](#)] [[PubMed](#)]
113. Liu, D.; Wang, S.; Liu, S.; Wang, Q.; Che, X.; Wu, G. Frontiers in sarcopenia: Advancements in diagnostics, molecular mechanisms, and therapeutic strategies. *Mol. Aspects Med.* **2024**, *97*, 101270. [[CrossRef](#)] [[PubMed](#)]
114. Yang, W.; Si, S.C.; Wang, W.H.; Li, J.; Ma, Y.X.; Zhao, H.; Liu, J. Gut dysbiosis in primary sarcopenia: Potential mechanisms and implications for novel microbiome-based therapeutic strategies. *Front. Microbiol.* **2025**, *16*, 1526764. [[CrossRef](#)] [[PubMed](#)]
115. Salom Vendrell, C.; García Tercero, E.; Moro Hernández, J.B.; Cedeno-Veloz, B.A. Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment. *Nutrients* **2023**, *15*, 4149. [[CrossRef](#)]
116. Bahadoran, Z.; Mirmiran, P.; Ghasemi, A. Type 2 diabetes-related sarcopenia: Role of nitric oxide. *Nutr. Metab.* **2024**, *21*, 107. [[CrossRef](#)]
117. Lin, C.C.; Ou, H.Y.; Hsu, H.Y.; Cheng, K.P.; Hsieh, T.J.; Yeh, C.H.; Su, F.C.; Kuo, L.C. Beyond Sarcopenia: Older adults with type II diabetes mellitus tend to experience an elevated risk of poor dynamic balance—a case-control study. *BMC Geriatr.* **2022**, *22*, 138. [[CrossRef](#)]
118. Liu, Z.; Guo, Y.; Zheng, C. Type 2 diabetes mellitus related sarcopenia: A type of muscle loss distinct from sarcopenia and disuse muscle atrophy. *Front. Endocrinol.* **2024**, *15*, 1375610. [[CrossRef](#)]
119. Lee, C.G.; Boyko, E.J.; Strotmeyer, E.S.; Lewis, C.E.; Cawthon, P.M.; Hoffman, A.R.; Everson-Rose, S.A.; Barrett-Connor, E.; Orwoll, E.S. Osteoporotic Fractures in Men Study Research Group. Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. *J. Am. Geriatr. Soc.* **2011**, *59*, 1217–1224. [[CrossRef](#)]
120. Sanz-Cánovas, J.; López-Sampalo, A.; Cobos-Palacios, L.; Ricci, M.; Hernández-Negrín, H.; Mancebo-Sevilla, J.J.; Álvarez-Recio, E.; López-Carmona, M.D.; Pérez-Belmonte, L.M.; Gómez-Huelgas, R.; et al. Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia. *Int. J. Environ. Res. Public Health* **2022**, *19*, 8677. [[CrossRef](#)]
121. Landi, F.; Onder, G.; Bernabei, R. Sarcopenia and diabetes: Two sides of the same coin. *J. Am. Med. Dir. Assoc.* **2013**, *14*, 540–541. [[CrossRef](#)]
122. Pereira, S.; Marlist, E.B.; Morais, J.A.; Chevalier, S.; Gougeon, R. Insulin resistance of protein metabolism in type 2 diabetes. *Diabetes* **2008**, *57*, 56–63. [[CrossRef](#)] [[PubMed](#)]
123. Nygren, J.; Nair, K.S. Differential regulation of protein dynamics in splanchnic and skeletal muscle beds by insulin and amino acids in healthy human subjects. *Diabetes* **2003**, *52*, 1377–1385. [[CrossRef](#)] [[PubMed](#)]

124. Tan, S.; Gunendi, Z.; Meray, J.; Yetkin, İ. The evaluation of muscle strength and architecture in type 1 diabetes mellitus: A cross-sectional study. *BMC Endocr. Disord.* **2022**, *22*, 153. [[CrossRef](#)] [[PubMed](#)]
125. Tabara, Y.; Ikezoe, T.; Yamanaka, M.; Setoh, K.; Segawa, H.; Kawaguchi, T.; Kosugi, S.; Nakayama, T.; Ichihashi, N.; Tsuboyama, T.; et al. Advanced Glycation End Product Accumulation Is Associated with Low Skeletal Muscle Mass, Weak Muscle Strength, and Reduced Bone Density: The Nagahama Study. *J. Gerontol. A Biol. Sci. Med. Sci.* **2019**, *74*, 1446–1453. [[CrossRef](#)]
126. Mesinovic, J.; Zengin, A.; De Courten, B.; Ebeling, P.R.; Scott, D. Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. *Diabetes Metab. Syndr. Obes.* **2019**, *12*, 1057–1072. [[CrossRef](#)]
127. Giannakogeorgou, A.; Roden, M.; Pafili, K. Diabetes mellitus as a multisystem disease: Understanding subtypes, complications, and the link with steatotic liver diseases in humans. *Hormones* **2025**. [[CrossRef](#)]
128. Park, Y.; Kim, S.T.; Kim, Y.M.; Han, H.S.; Yoon, Y.S. Role of diabetes-related inflammation in pancreatic cancer evaluated by aptamer-based detection of circulating tumor cells in a streptozotocin-induced Panc02-transplanted murine model. *Ann. Hepatobiliary Pancreat. Surg.* **2025**, *29*, 343–352. [[CrossRef](#)]
129. Haddad, F.; Zaldivar, F.; Cooper, D.M.; Adams, G.R. IL-6-induced skeletal muscle atrophy. *J. Appl. Physiol.* **2005**, *98*, 911–917. [[CrossRef](#)]
130. Goyal, R.; Faizy, A.F.; Siddiqui, S.S.; Singhai, M. Evaluation of TNF- $\alpha$  and IL-6 Levels in Obese and Non-obese Diabetics: Pre- and Postinsulin Effects. *N. Am. J. Med. Sci.* **2012**, *4*, 180–184. [[CrossRef](#)]
131. Liu, Y.; Li, Z.; Wang, R.; Zhang, J.; Gerstein, H.; Zhao, A.; Zhang, C.; Lip, G.Y.H.; Van Spall, H.G.C.; Li, G. Relationship between sarcopenia and type 2 diabetes mellitus among adults with prediabetes: Evidence from a prospective cohort study. *Diabetol. Metab. Syndr.* **2025**, *17*, 379. [[CrossRef](#)] [[PubMed](#)]
132. Chen, H.; Huang, X.; Dong, M.; Wen, S.; Zhou, L.; Yuan, X. The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy. *Diabetes Metab. Syndr. Obes.* **2023**, *16*, 1541–1554. [[CrossRef](#)] [[PubMed](#)]
133. Xu, Y.; Hu, T.; Shen, Y.; Wang, Y.; Bao, Y.; Ma, X. Association of skeletal muscle mass and its change with diabetes occurrence: A population-based cohort study. *Diabetol. Metab. Syndr.* **2023**, *15*, 53. [[CrossRef](#)] [[PubMed](#)]
134. Ye, C.; Kong, L.; Wang, Y.; Zheng, J.; Xu, M.; Xu, Y.; Li, M.; Zhao, Z.; Lu, J.; Chen, Y.; et al. Causal associations of sarcopenia-related traits with cardiometabolic disease and Alzheimer’s disease and the mediating role of insulin resistance: A Mendelian randomization study. *Aging Cell* **2023**, *22*, e13923. [[CrossRef](#)]
135. Ni, Y.; Fan, D. Diabetes mellitus is a risk factor for low bone mass-related fractures: A meta-analysis of cohort studies. *Medicine* **2017**, *96*, e8811. [[CrossRef](#)]
136. Pechmann, L.M.; Petterle, R.R.; Moreira, C.A.; Borba, V.Z.C. Osteosarcopenia and trabecular bone score in patients with type 2 diabetes mellitus. *Arch. Endocrinol. Metab.* **2021**, *65*, 801–810. [[CrossRef](#)]
137. Sipilä, S.; Törmäkangas, T.; Sillanpää, E.; Aukee, P.; Kujala, U.M.; Kovanen, V.; Laakkonen, E.K. Muscle and bone mass in middle-aged women: Role of menopausal status and physical activity. *J. Cachexia Sarcopenia Muscle* **2020**, *11*, 698–709. [[CrossRef](#)]
138. Abbatecola, A.M.; Paolisso, G.; Fattoretti, P.; Evans, W.J.; Fiore, V.; Dicioccio, L.; Lattanzio, F. Discovering pathways of sarcopenia in older adults: A role for insulin resistance on mitochondria dysfunction. *J. Nutr. Health Aging* **2011**, *15*, 890–895. [[CrossRef](#)]
139. Greco, E.A.; Pietschmann, P.; Migliaccio, S. Osteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly. *Front. Endocrinol.* **2019**, *10*, 255. [[CrossRef](#)]
140. Çakmak, G.; Ganidağlı, S.; Efendioğlu, E.M.; Öztürk, E.; Öztürk, Z.A. Do Long-Term Complications of Type 2 Diabetes Increase Susceptibility to Geriatric Syndromes in Older Adults? *Medicina* **2021**, *57*, 968. [[CrossRef](#)]
141. Hashimoto, Y.; Takahashi, F.; Okamura, T.; Hamaguchi, M.; Fukui, M. Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes. *Metabolism* **2023**, *144*, 155585. [[CrossRef](#)] [[PubMed](#)]
142. Denison, H.J.; Cooper, C.; Sayer, A.A.; Robinson, S.M. Prevention and optimal management of sarcopenia: A review of combined exercise and nutrition interventions to improve muscle outcomes in older people. *Clin. Interv. Aging* **2015**, *10*, 859–869. [[CrossRef](#)]
143. Gómez-Cabello, A.; Vicente Rodríguez, G.; Vila-Maldonado, S.; Casajús, J.A.; Ara, I. Aging and body composition: The sarcopenic obesity in Spain. *Nutr. Hosp.* **2012**, *27*, 22–30. [[CrossRef](#)] [[PubMed](#)]
144. Wei, S.; Nguyen, T.T.; Zhang, Y.; Ryu, D.; Gariani, K. Sarcopenic obesity: Epidemiology, pathophysiology, cardiovascular disease, mortality, and management. *Front. Endocrinol.* **2023**, *14*, 1185221. [[CrossRef](#)] [[PubMed](#)]
145. Donini, L.M.; Busetto, L.; Bischoff, S.C.; Cederholm, T.; Ballesteros-Pomar, M.D.; Batsis, J.A.; Bauer, J.M.; Boirie, Y.; Cruz-Jentoft, A.J.; Dicker, D.; et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. *Obes. Facts* **2022**, *15*, 321–335. [[CrossRef](#)]
146. Batsis, J.A.; Villareal, D.T. Sarcopenic obesity in older adults: Aetiology, epidemiology and treatment strategies. *Nat. Rev. Endocrinol.* **2018**, *14*, 513–537. [[CrossRef](#)]
147. Nedelcu, A.D.; Uzun, A.B.; Ciortea, V.M.; Irsay, L.; Stanciu, L.E.; Iliescu, D.M.; Popa, F.L.; Iliescu, M.G. Genetic Patterns Related with the Development and Progression of Sarcopenia and Sarcopenic Obesity: A Systematic Review. *Medicina* **2025**, *61*, 866. [[CrossRef](#)]

148. Prado, C.M.; Batsis, J.A.; Donini, L.M.; Gonzalez, M.C.; Siervo, M. Sarcopenic obesity in older adults: A clinical overview. *Nat. Rev. Endocrinol.* **2024**, *20*, 261–277. [[CrossRef](#)]
149. Oliveira, T.M.; Roriz, A.K.C.; Barreto-Medeiros, J.M.; Ferreira, A.J.F.; Ramos, L. Sarcopenic obesity in community-dwelling older women, determined by different diagnostic methods. *Nutr. Hosp.* **2019**, *36*, 1267–1272. [[CrossRef](#)]
150. Abete, I.; Konieczna, J.; Zulet, M.A.; Galmés-Panades, A.M.; Ibero-Baraibar, I.; Babio, N.; Estruch, R.; Vidal, J.; Toledo, E.; Razquin, C.; et al. Association of lifestyle factors and inflammation with sarcopenic obesity: Data from the PREDIMED-Plus trial. *J. Cachexia Sarcopenia Muscle* **2019**, *10*, 974–984. [[CrossRef](#)]
151. Minniti, G.; Pescinini-Salzedas, L.M.; Minniti, G.; Laurindo, L.F.; Barbalho, S.M.; Vargas Sinatora, R.; Sloan, L.A.; Haber, R.S.A.; Araújo, A.C.; Quesada, K.; et al. Organokines, Sarcopenia, and Metabolic Repercussions: The Vicious Cycle and the Interplay with Exercise. *Int. J. Mol. Sci.* **2022**, *23*, 13452. [[CrossRef](#)] [[PubMed](#)]
152. Aslam, M.A.; Ma, E.B.; Huh, J.Y. Pathophysiology of sarcopenia: Genetic factors and their interplay with environmental factors. *Metabolism* **2023**, *149*, 155711. [[CrossRef](#)] [[PubMed](#)]
153. Semenova, E.A.; Pranckevičienė, E.; Bondareva, E.A.; Gabdrakhmanova, L.J.; Ahmetov, I.I. Identification and Characterization of Genomic Predictors of Sarcopenia and Sarcopenic Obesity Using UK Biobank Data. *Nutrients* **2023**, *15*, 758. [[CrossRef](#)] [[PubMed](#)]
154. Feng, Z.; Xia, J.; Yu, J.; Wang, J.; Yin, S.; Yang, J.; Wu, T.; Zhang, Z.; Yan, W.; Wang, S.; et al. Pathophysiological Mechanisms Underlying Sarcopenia and Sarcopenic Obesity: A Systematic Review and Meta-Analysis of Biomarker Evidence. *Int. J. Mol. Sci.* **2025**, *26*, 5113. [[CrossRef](#)]
155. Silva, J.K.; Aguiar, O.B.; Diniz, M.F.H.S.; Braga, J.U.; Griep, R.H.; Fonseca, M.J.M.D. Performance of the “a body shape index” as a discriminator of obesity and sarcopenic obesity—ELSA-Brasil. *Cien. Saude Colet.* **2025**, *30*, e03162023. [[CrossRef](#)]
156. Pavlovskaya, E.V.; Kislyak, O.A.; Starodubova, A.V. Principles of diet therapy for sarcopenic obesity: A review. *Ter. Arkhiv* **2025**, *97*, 571–579. [[CrossRef](#)]
157. Briguglio, M.; Sirtori, P.; Mangiavini, L.; Wainwright, T.W.; Peretti, G.M.; Banfi, G. NCPD Tests: Undernutrition, Sarcopenia, Sarcopenic Obesity, and Sarcopenic Undernutrition: A Cross-sectional View on Patients Before Total Joint Arthroplasty. *Orthop. Nurs.* **2024**, *43*, E19. [[CrossRef](#)]
158. Calvani, R.; Marini, F.; Cesari, M.; Buford, T.W.; Manini, T.M.; Pahor, M.; Leeuwenburgh, C.; Bernabei, R.; Landi, F.; Marzetti, E. Systemic inflammation, body composition, and physical performance in old community-dwellers. *J. Cachexia Sarcopenia Muscle* **2017**, *8*, 69–77. [[CrossRef](#)]
159. Batsis, J.A.; Mackenzie, T.A.; Barre, L.K.; Lopez-Jimenez, F.; Bartels, S.J. Sarcopenia, sarcopenic obesity and mortality in older adults: Results from the National Health and Nutrition Examination Survey III. *Eur. J. Clin. Nutr.* **2014**, *68*, 1001–1007. [[CrossRef](#)]
160. Tyrovolas, S.; Koyanagi, A.; Olaya, B.; Ayuso-Mateos, J.L.; Miret, M.; Chatterji, S.; Tobiasz-Adamczyk, B.; Koskinen, S.; Leonardi, M.; Haro, J.M. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: A multi-continent study. *J. Cachexia Sarcopenia Muscle* **2016**, *7*, 312–321. [[CrossRef](#)]
161. Sugimoto, T.; Kuroda, Y.; Matsumoto, N.; Uchida, K.; Kishino, Y.; Saji, N.; Niida, S.; Sakurai, T. Cross-Sectional Associations of Sarcopenia and Its Components with Neuropsychological Performance among Memory Clinic Patients with Mild Cognitive Impairment and Alzheimer’s Disease. *J. Frailty Aging* **2022**, *11*, 182–189. [[CrossRef](#)]
162. Su, C.; Zhang, S.; Zheng, Q.; Miao, J.; Guo, J. Prevalence and correlation of sarcopenia with Alzheimer’s disease: A systematic review and meta-analysis. *PLoS ONE* **2025**, *20*, e0318920. [[CrossRef](#)] [[PubMed](#)]
163. Hart, A.; Cordova-Rivera, L.; Barker, F.; Sayer, A.A.; Granic, A.; Yarnall, A.J. The prevalence of sarcopenia in Parkinson’s disease and related disorders- a systematic review. *Neurol. Sci.* **2023**, *44*, 4205–4217. [[CrossRef](#)] [[PubMed](#)]
164. Beeri, M.S.; Leugrants, S.E.; Delbono, O.; Bennett, D.A.; Buchman, A.S. Sarcopenia is associated with incident Alzheimer’s dementia, mild cognitive impairment, and cognitive decline. *J. Am. Geriatr. Soc.* **2021**, *69*, 1826–1835. [[CrossRef](#)] [[PubMed](#)]
165. Fujisawa, C.; Umegaki, H.; Okamoto, K.; Nakashima, H.; Kuzuya, M.; Toba, K.; Sakurai, T. Physical Function Differences Between the Stages from Normal Cognition to Moderate Alzheimer Disease. *J. Am. Med. Dir. Assoc.* **2017**, *18*, 368.e9–368.e15. [[CrossRef](#)]
166. Murata, S.; Ono, R.; Sugimoto, T.; Toba, K.; Sakurai, T. Functional Decline and Body Composition Change in Older Adults with Alzheimer Disease: A Retrospective Cohort Study at a Japanese Memory Clinic. *Alzheimer Dis. Assoc. Disord.* **2021**, *35*, 36–43. [[CrossRef](#)]
167. Michaud, M.; Balardy, L.; Moulis, G.; Gaudin, C.; Peyrot, C.; Vellas, B.; Cesari, M.; Nourhashemi, F. Proinflammatory cytokines, aging, and age-related diseases. *J. Am. Med. Dir. Assoc.* **2013**, *14*, 877–882. [[CrossRef](#)]
168. Mecocci, P.; Boccardi, V.; Cecchetti, R.; Bastiani, P.; Scamosci, M.; Ruggiero, C.; Baroni, M. A Long Journey into Aging, Brain Aging, and Alzheimer’s Disease Following the Oxidative Stress Tracks. *J. Alzheimers Dis.* **2018**, *62*, 1319–1335. [[CrossRef](#)]
169. Cai, Y.; Feng, F.; Wei, Q.; Jiang, Z.; Ou, R.; Shang, H. Sarcopenia in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis. *Front. Neurol.* **2021**, *12*, 598035. [[CrossRef](#)]
170. Lima, D.P.; de Almeida, S.B.; Bonfadini, J.C.; de Luna, J.R.G.; de Alencar, M.S.; Pinheiro-Neto, E.B.; Viana-Júnior, A.B.; Veras, S.R.O.; Sobreira-Neto, M.A.; Roriz-Filho, J.S.; et al. Clinical correlates of sarcopenia and falls in Parkinson’s disease. *PLoS ONE* **2020**, *15*, e0227238. [[CrossRef](#)]

171. Drey, M.; Krieger, B.; Sieber, C.C.; Bauer, J.M.; Hettwer, S.; Bertsch, T.; DISARCO Study Group. Motoneuron loss is associated with sarcopenia. *J. Am. Med. Dir. Assoc.* **2014**, *15*, 435–439. [[CrossRef](#)] [[PubMed](#)]
172. Krenovsky, J.P.; Bötzel, K.; Ceballos-Baumann, A.; Fietzek, U.M.; Schoser, B.; Maetzler, W.; Ferrari, U.; Drey, M. Interrelation between Sarcopenia and the Number of Motor Neurons in Patients with Parkinsonian Syndromes. *Gerontology* **2020**, *66*, 409–415. [[CrossRef](#)] [[PubMed](#)]
173. Basualto-Alarcón, C.; Varela, D.; Duran, J.; Maass, R.; Estrada, M. Sarcopenia and Androgens: A Link between Pathology and Treatment. *Front. Endocrinol.* **2014**, *5*, 217. [[CrossRef](#)] [[PubMed](#)]
174. Amini, N.; Ibn Hach, M.; Lapauw, L.; Dupont, J.; Vercauteren, L.; Verschueren, S.; Tournoy, J.; Gielen, E. Meta-analysis on the interrelationship between sarcopenia and mild cognitive impairment, Alzheimer’s disease and other forms of dementia. *J. Cachexia Sarcopenia Muscle* **2024**, *15*, 1240–1253. [[CrossRef](#)]
175. Kondoh, H.; Kameda, M. Metabolites in aging and aging-relevant diseases: Frailty, sarcopenia and cognitive decline. *Geriatr. Gerontol. Int.* **2024**, *24* (Suppl. S1), 44–48. [[CrossRef](#)]
176. Chen, X.; Cao, M.; Liu, M.; Liu, S.; Zhao, Z.; Chen, H. Association between sarcopenia and cognitive impairment in the older people: A meta-analysis. *Eur. Geriatr. Med.* **2022**, *13*, 771–787. [[CrossRef](#)]
177. Cesari, M.; Landi, F.; Vellas, B.; Bernabei, R.; Marzetti, E. Sarcopenia and physical frailty: Two sides of the same coin. *Front. Aging Neurosci.* **2014**, *6*, 192. [[CrossRef](#)]
178. Kosyрева, A.M.; Sentyabreva, A.V.; Tsvetkov, I.S.; Makarova, O.V. Alzheimer’s Disease and Inflammaging. *Brain Sci.* **2022**, *12*, 1237. [[CrossRef](#)]
179. Du, H.; Yu, M.; Xue, H.; Lu, X.; Chang, Y.; Li, Z. Association between sarcopenia and cognitive function in older Chinese adults: Evidence from the China health and retirement longitudinal study. *Front. Public Health* **2022**, *10*, 1078304. [[CrossRef](#)]
180. Boyle, P.A.; Buchman, A.S.; Wilson, R.S.; Leurgans, S.E.; Bennett, D.A. Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. *Arch. Neurol.* **2009**, *66*, 1339–1344. [[CrossRef](#)]
181. Casati, M.; Costa, A.S.; Capitanio, D.; Ponzoni, L.; Ferri, E.; Agostini, S.; Lori, E. The Biological Foundations of Sarcopenia: Established and Promising Markers. *Front. Med.* **2019**, *6*, 184. [[CrossRef](#)] [[PubMed](#)]
182. Shigemoto, K.; Kubo, S.; Mori, S.; Yamada, S.; Akiyoshi, T.; Miyazaki, T. Muscle weakness and neuromuscular junctions in aging and disease. *Geriatr. Gerontol. Int.* **2010**, *10* (Suppl. S1), S137–S147. [[CrossRef](#)] [[PubMed](#)]
183. Moreira-Pais, A.; Ferreira, R.; Oliveira, P.A.; Duarte, J.A. A neuromuscular perspective of sarcopenia pathogenesis: Deciphering the signaling pathways involved. *Geroscience* **2022**, *44*, 1199–1213. [[CrossRef](#)] [[PubMed](#)]
184. Rudolf, R.; Khan, M.M.; Labeit, S.; Deschenes, M.R. Degeneration of neuromuscular junction in age and dystrophy. *Front. Aging Neurosci.* **2014**, *6*, 99. [[CrossRef](#)]
185. Yang, Y.; Xiao, M.; Leng, L.; Jiang, S.; Feng, L.; Pan, G.; Li, Z.; Wang, Y.; Wang, J.; Wen, Y.; et al. A systematic review and meta-analysis of the prevalence and correlation of mild cognitive impairment in sarcopenia. *J. Cachexia Sarcopenia Muscle* **2023**, *14*, 45–56. [[CrossRef](#)]
186. Zhang, J.; Jia, X.; Li, Y.; Li, H.; Yang, Q. The longitudinal bidirectional association between sarcopenia and cognitive function in community-dwelling older adults: Findings from the China Health and Retirement Longitudinal Study. *J. Glob. Health* **2023**, *13*, 04182. [[CrossRef](#)]
187. Cacciatore, S.; Calvani, R.; Marzetti, E.; Picca, A.; Coelho-Júnior, H.J.; Martone, A.M.; Massaro, C.; Tosato, M.; Landi, F. Low Adherence to Mediterranean Diet Is Associated with Probable Sarcopenia in Community-Dwelling Older Adults: Results from the Longevity Check-Up (Lookup) 7+ Project. *Nutrients* **2023**, *15*, 1026. [[CrossRef](#)]
188. Peng, T.C.; Chen, W.L.; Wu, L.W.; Chang, Y.W.; Kao, T.W. Sarcopenia and cognitive impairment: A systematic review and meta-analysis. *Clin Nutr.* **2020**, *39*, 2695–2701. [[CrossRef](#)]
189. Yuan, S.; Larsson, S.C. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. *Metabolism* **2023**, *144*, 155533. [[CrossRef](#)]
190. Mitchell, W.K.; Williams, J.; Atherton, P.; Larvin, M.; Lund, J.; Narici, M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. *Front. Physiol.* **2012**, *3*, 260. [[CrossRef](#)]
191. Seo, M.W.; Jung, S.W.; Kim, S.W.; Lee, J.M.; Jung, H.C.; Song, J.K. Effects of 16 Weeks of Resistance Training on Muscle Quality and Muscle Growth Factors in Older Adult Women with Sarcopenia: A Randomized Controlled Trial. *Int. J. Environ. Res. Public Health* **2021**, *18*, 6762. [[CrossRef](#)]
192. Billot, M.; Calvani, R.; Urtamo, A.; Sánchez-Sánchez, J.L.; Cicolari-Micaldi, C.; Chang, M.; Roller-Wirnsberger, R.; Wirnsberger, G.; Sinclair, A.; Vaquero-Pinto, N.; et al. Preserving Mobility in Older Adults with Physical Frailty and Sarcopenia: Opportunities, Challenges, and Recommendations for Physical Activity Interventions. *Clin. Interv. Aging* **2020**, *15*, 1675–1690. [[CrossRef](#)]
193. Marzetti, E.; Calvani, R.; Tosato, M.; Cesari, M.; Di Bari, M.; Cherubini, A.; Collamati, A.; D’Angelo, E.; Pahor, M.; Bernabei, R.; et al. Sarcopenia: An overview. *Aging Clin. Exp. Res.* **2017**, *29*, 11–17. [[CrossRef](#)] [[PubMed](#)]

194. Sun, R.; Wan, J.; Tang, J.; Deng, Y.; Zhang, M.; Liu, C.; Li, J.; Zhang, Q. Effectiveness of resistance training on body composition, muscle strength, and biomarker in sarcopenic older adults: A meta-analysis of randomized controlled trials. *Arch. Gerontol. Geriatr.* **2025**, *128*, 105595. [[CrossRef](#)] [[PubMed](#)]
195. Welle, S. Cellular and molecular basis of age-related sarcopenia. *Can. J. Appl. Physiol.* **2002**, *27*, 19–41. [[CrossRef](#)] [[PubMed](#)]
196. Aragon, A.A.; Tipton, K.D.; Schoenfeld, B.J. Age-related muscle anabolic resistance: Inevitable or preventable? *Nutr. Rev.* **2023**, *81*, 441–454. [[CrossRef](#)]
197. Ferrucci, L.; Fabbri, E. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat. Rev. Cardiol.* **2018**, *15*, 505–522. [[CrossRef](#)]
198. Dalle, S.; Rossmeislova, L.; Koppo, K. The Role of Inflammation in Age-Related Sarcopenia. *Front. Physiol.* **2017**, *8*, 1045. [[CrossRef](#)]
199. Liu, G.; Jiang, S.; Xie, W.; Liu, X.; Yang, G.; Lu, W.; Li, H.; Liu, Z.; Xiao, W.; Li, Y. Biomarkers for sarcopenia, muscle mass, muscle strength, and physical performance: An umbrella review. *J. Transl. Med.* **2025**, *23*, 650. [[CrossRef](#)]
200. Lu, Y.; Niti, M.; Yap, K.B.; Tan, C.T.Y.; Zin Nyunt, M.S.; Feng, L.; Tan, B.Y.; Chan, G.; Khoo, S.A.; Chan, S.M.; et al. Assessment of Sarcopenia Among Community-Dwelling At-Risk Frail Adults Aged 65 Years and Older Who Received Multidomain Lifestyle Interventions: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Netw. Open* **2019**, *2*, e1913346. [[CrossRef](#)]
201. Paterson, D.H.; Warburton, D.E. Physical activity and functional limitations in older adults: A systematic review related to Canada's Physical Activity Guidelines. *Int. J. Behav. Nutr. Phys. Act.* **2010**, *7*, 38. [[CrossRef](#)] [[PubMed](#)]
202. Beckwée, D.; Delaere, A.; Aelbrecht, S.; Baert, V.; Beaudart, C.; Bruyere, O.; de Saint-Hubert, M.; Bautmans, I. Exercise Interventions for the Prevention and Treatment of Sarcopenia. A Systematic Umbrella Review. *J. Nutr. Health Aging* **2019**, *23*, 494–502. [[CrossRef](#)]
203. Chang, K.V.; Wu, W.T.; Chen, Y.H.; Chen, L.R.; Hsu, W.H.; Lin, Y.L.; Han, D.S. Enhanced serum levels of tumor necrosis factor- $\alpha$ , interleukin-1 $\beta$ , and -6 in sarcopenia: Alleviation through exercise and nutrition intervention. *Aging* **2023**, *15*, 13471–13485. [[CrossRef](#)] [[PubMed](#)]
204. Grenham, S.; Clarke, G.; Cryan, J.F.; Dinan, T.G. Brain-gut-microbe communication in health and disease. *Front. Physiol.* **2011**, *2*, 94. [[CrossRef](#)]
205. Carabotti, M.; Scirocco, A.; Maselli, M.A.; Severi, C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. *Ann. Gastroenterol.* **2015**, *28*, 203–209. [[PubMed](#)]
206. Kim, C.S.; Cha, L.; Sim, M.; Jung, S.; Chun, W.Y.; Baik, H.W.; Shin, D.M. Probiotic Supplementation Improves Cognitive Function and Mood with Changes in Gut Microbiota in Community-Dwelling Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. *J. Gerontol. A Biol. Sci. Med. Sci.* **2021**, *76*, 32–40. [[CrossRef](#)]
207. Kesika, P.; Suganthy, N.; Sivamaruthi, B.S.; Chaiyasut, C. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease. *Life Sci.* **2021**, *264*, 118627. [[CrossRef](#)]
208. Yang, J.; Liang, J.; Hu, N.; He, N.; Liu, B.; Liu, G.; Qin, Y. The Gut Microbiota Modulates Neuroinflammation in Alzheimer's Disease: Elucidating Crucial Factors and Mechanistic Underpinnings. *CNS Neurosci. Ther.* **2024**, *30*, e70091. [[CrossRef](#)]
209. Pellegrini, C.; Antonioli, L.; Calderone, V.; Colucci, R.; Fornai, M.; Blandizzi, C. Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? *Prog. Neurobiol.* **2020**, *191*, 101806. [[CrossRef](#)]
210. Wu, S.; Liu, X.; Jiang, R.; Yan, X.; Ling, Z. Roles and Mechanisms of Gut Microbiota in Patients with Alzheimer's Disease. *Front. Aging Neurosci.* **2021**, *13*, 650047. [[CrossRef](#)]
211. Xu, W.; Huang, Y.; Zhou, R. NLRP3 inflammasome in neuroinflammation and central nervous system diseases. *Cell Mol Immunol.* **2025**, *22*, 341–355. [[CrossRef](#)] [[PubMed](#)]
212. Rutsch, A.; Kantsjö, J.B.; Ronchi, F. The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology. *Front. Immunol.* **2020**, *11*, 604179. [[CrossRef](#)] [[PubMed](#)]
213. Shukla, P.K.; Delotterie, D.F.; Xiao, J.; Pierre, J.F.; Rao, R.; McDonald, M.P.; Khan, M.M. Alterations in the Gut-Microbial-Inflammasome-Brain Axis in a Mouse Model of Alzheimer's Disease. *Cells* **2021**, *10*, 779. [[CrossRef](#)] [[PubMed](#)]
214. Barry, D.J.; Wu, S.S.X.; Cooke, M.B. The Relationship Between Gut Microbiota, Muscle Mass and Physical Function in Older Individuals: A Systematic Review. *Nutrients* **2024**, *17*, 81. [[CrossRef](#)]
215. Ticinesi, A.; Nouvenne, A.; Cerundolo, N.; Catania, P.; Prati, B.; Tana, C.; Meschi, T. Gut Microbiota, Muscle Mass and Function in Aging: A Focus on Physical Frailty and Sarcopenia. *Nutrients* **2019**, *11*, 1633. [[CrossRef](#)]
216. Liu, C.; Cheung, W.H.; Li, J.; Chow, S.K.; Yu, J.; Wong, S.H.; Ip, M.; Sung, J.J.Y.; Wong, R.M.Y. Understanding the gut microbiota and sarcopenia: A systematic review. *J. Cachexia Sarcopenia Muscle* **2021**, *12*, 1393–1407. [[CrossRef](#)]
217. Asaoka, D.; Toda, K.; Yoshimoto, S.; Katsumata, N.; Odamaki, T.; Iwabuchi, N.; Tanaka, M.; Xiao, J.Z.; Nishikawa, Y.; Nomura, O.; et al. Sex-Specific Associations of Gut Microbiota Composition with Sarcopenia Defined by the Asian Working Group for Sarcopenia 2019 Consensus in Older Outpatients: Prospective Cross-Sectional Study in Japan. *Nutrients* **2025**, *17*, 1746. [[CrossRef](#)]

218. Ticinesi, A.; Lauretani, F.; Milani, C.; Nouvenne, A.; Tana, C.; Del Rio, D.; Maggio, M.; Ventura, M.; Meschi, T. Aging Gut Microbiota at the Cross-Road between Nutrition, Physical Frailty, and Sarcopenia: Is There a Gut-Muscle Axis? *Nutrients* **2017**, *9*, 1303. [[CrossRef](#)]
219. Mohebbi, N.; Weigel, M.; Hain, T.; Sütel, M.; Bull, J.; Kreikemeyer, B.; Breitrück, A. Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity. *Biomed. Pharmacother.* **2023**, *167*, 115568. [[CrossRef](#)]
220. Guo, T.T.; Zhang, Z.; Sun, Y.; Zhu, R.Y.; Wang, F.X.; Ma, L.J.; Jiang, L.; Liu, H.D. Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson's Disease. *Nutrients* **2023**, *15*, 930. [[CrossRef](#)]
221. Tabat, M.W.; Marques, T.M.; Markgren, M.; Löfvendahl, L.; Brummer, R.J.; Wall, R. Acute Effects of Butyrate on Induced Hyperpermeability and Tight Junction Protein Expression in Human Colonic Tissues. *Biomolecules* **2020**, *10*, 766. [[CrossRef](#)] [[PubMed](#)]
222. Liu, T.; Zhang, L.; Joo, D.; Sun, S.-C. NF- $\kappa$ B signaling in inflammation. *Signal Transduct. Target. Ther.* **2017**, *2*, 17023. [[CrossRef](#)] [[PubMed](#)]
223. Huang, C.C.; Tsai, S.F.; Liu, S.C.; Yeh, M.C.; Hung, H.C.; Lee, C.W.; Cheng, C.L.; Hsu, P.L.; Kuo, Y.M. Insulin Mediates Lipopolysaccharide-Induced Inflammatory Responses and Oxidative Stress in BV2 Microglia. *J. Inflamm. Res.* **2024**, *17*, 7993–8008. [[CrossRef](#)] [[PubMed](#)]
224. Chiarini, A.; Gui, L.; Viviani, C.; Armato, U.; Dal Prà, I. NLRP3 Inflammasome's Activation in Acute and Chronic Brain Diseases—An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes. *Biomedicines* **2023**, *11*, 999. [[CrossRef](#)]
225. Grunow, J.J.; Gan, T.; Lewald, H.; Martyn, J.A.J.; Blobner, M.; Schaller, S.J. Insulin signaling in skeletal muscle during inflammation and/or immobilisation. *Intensive Care Med. Exp.* **2023**, *11*, 16. [[CrossRef](#)]
226. Zhang, Y.; Wang, J.; Wang, X.; Gao, T.; Tian, H.; Zhou, D.; Zhang, L.; Li, G.; Wang, X. The autophagic-lysosomal and ubiquitin proteasome systems are simultaneously activated in the skeletal muscle of gastric cancer patients with cachexia. *Am. J. Clin. Nutr.* **2020**, *111*, 570–579. [[CrossRef](#)]
227. Ballesteros, J.; Rivas, D.; Duque, G. The Role of the Kynurenine Pathway in the Pathophysiology of Frailty, Sarcopenia, and Osteoporosis. *Nutrients* **2023**, *15*, 3132. [[CrossRef](#)]
228. Ticinesi, A.; Tana, C.; Nouvenne, A. The intestinal microbiome and its relevance for functionality in older persons. *Curr. Opin. Clin. Nutr. Metab. Care* **2019**, *22*, 4–12. [[CrossRef](#)]
229. García-Domínguez, M. Pathological and Inflammatory Consequences of Aging. *Biomolecules* **2025**, *15*, 404. [[CrossRef](#)]
230. Strasser, B.; Ticinesi, A. Intestinal microbiome in normal ageing, frailty and cognition decline. *Curr. Opin. Clin. Nutr. Metab. Care* **2023**, *26*, 8–16. [[CrossRef](#)]
231. Ticinesi, A.; Nouvenne, A.; Cerundolo, N.; Parise, A.; Mena, P.; Meschi, T. The interaction between Mediterranean diet and intestinal microbiome: Relevance for preventive strategies against frailty in older individuals. *Aging Clin. Exp. Res.* **2024**, *36*, 58. [[CrossRef](#)]
232. Ghosh, T.S.; Rampelli, S.; Jeffery, I.B.; Santoro, A.; Neto, M.; Capri, M.; Giampieri, E.; Jennings, A.; Candela, M.; Turroni, S.; et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: The NU-AGE 1-year dietary intervention across five European countries. *Gut* **2020**, *69*, 1218–1228. [[CrossRef](#)] [[PubMed](#)]
233. Kemmler, W.; Kohl, M.; Fröhlich, M.; Jakob, F.; Engelke, K.; von Stengel, S.; Schoene, D. Effects of High-Intensity Resistance Training on Osteopenia and Sarcopenia Parameters in Older Men with Osteosarcopenia—One-Year Results of the Randomized Controlled Franconian Osteopenia and Sarcopenia Trial (FrOST). *J. Bone Miner. Res.* **2020**, *35*, 1634–1644. [[CrossRef](#)] [[PubMed](#)]
234. Kemmler, W.; Weineck, M.; Kohl, M.; von Stengel, S.; Giessing, J.; Fröhlich, M.; Schoene, D. High Intensity Resistance Exercise Training to Improve Body Composition and Strength in Older Men with Osteosarcopenia. Results of the Randomized Controlled Franconian Osteopenia and Sarcopenia Trial (FrOST). *Front. Sports Act. Living* **2020**, *2*, 4. [[CrossRef](#)] [[PubMed](#)]
235. Kemmler, W.; Kohl, M.; Fröhlich, M.; Engelke, K.; von Stengel, S.; Schoene, D. Effects of High-Intensity Resistance Training on Fitness and Fatness in Older Men with Osteosarcopenia. *Front. Physiol.* **2020**, *11*, 1014. [[CrossRef](#)]
236. Buskard, A.N.L.; Petrella, R.J. Resistance Training and Weight Loss in Older Adults: A Scoping Review. *Sports Med. Open* **2023**, *9*, 67. [[CrossRef](#)]
237. Zhang, M.; Song, Y.; Zhu, J.; Ding, P.; Chen, N. Effectiveness of low-load resistance training with blood flow restriction vs. conventional high-intensity resistance training in older people diagnosed with sarcopenia: A randomized controlled trial. *Sci. Rep.* **2024**, *14*, 28427. [[CrossRef](#)]
238. Coelho-Junior, H.J.; Calvani, R.; Azzolino, D.; Picca, A.; Tosato, M.; Landi, F.; Cesari, M.; Marzetti, E. Protein Intake and Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* **2022**, *19*, 8718. [[CrossRef](#)]

239. Montiel-Rojas, D.; Nilsson, A.; Santoro, A.; Bazzocchi, A.; de Groot, L.C.P.G.; Feskens, E.J.M.; Berendsen, A.A.M.; Madej, D.; Kaluza, J.; Pietruszka, B.; et al. Fighting Sarcopenia in Ageing European Adults: The Importance of the Amount and Source of Dietary Proteins. *Nutrients* **2020**, *12*, 3601. [[CrossRef](#)]
240. Coelho-Junior, H.J.; Marzetti, E.; Picca, A.; Cesari, M.; Uchida, M.C.; Calvani, R. Protein Intake and Frailty: A Matter of Quantity, Quality, and Timing. *Nutrients* **2020**, *12*, 2915. [[CrossRef](#)]
241. Martone, A.M.; Marzetti, E.; Calvani, R.; Picca, A.; Tosato, M.; Santoro, L.; Di Giorgio, A.; Nesci, A.; Sisto, A.; Santoliquido, A.; et al. Exercise and Protein Intake: A Synergistic Approach against Sarcopenia. *Biomed. Res. Int.* **2017**, *2017*, 2672435. [[CrossRef](#)] [[PubMed](#)]
242. Snijders, T.; Verdijk, L.B.; van Loon, L.J. The impact of sarcopenia and exercise training on skeletal muscle satellite cells. *Ageing Res. Rev.* **2009**, *8*, 328–338. [[CrossRef](#)] [[PubMed](#)]
243. Nilwik, R.; Snijders, T.; Leenders, M.; Groen, B.B.; van Kranenburg, J.; Verdijk, L.B.; van Loon, L.J. The decline in skeletal muscle mass with aging is mainly attributed to a reduction in type II muscle fiber size. *Exp. Gerontol.* **2013**, *48*, 492–498. [[CrossRef](#)] [[PubMed](#)]
244. Calvani, R.; Miccheli, A.; Landi, F.; Bossola, M.; Cesari, M.; Leeuwenburgh, C.; Sieber, C.C.; Bernabei, R.; Marzetti, E. Current nutritional recommendations and novel dietary strategies to manage sarcopenia. *J. Frailty Aging* **2013**, *2*, 38–53. [[CrossRef](#)]
245. Yoshimura, Y.; Matsumoto, A.; Inoue, T.; Okamura, M.; Kuzuya, M. Protein supplementation alone or combined with exercise for sarcopenia and physical frailty: A systematic review and meta-analysis of randomized controlled trials. *Arch. Gerontol. Geriatr.* **2025**, *131*, 105783. [[CrossRef](#)]
246. Mellen, R.H.; Giroto, O.S.; Marques, E.B.; Laurindo, L.F.; Grippa, P.C.; Mendes, C.G.; Garcia, L.N.H.; Bechara, M.D.; Barbalho, S.M.; Sinatora, R.V.; et al. Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review. *Biomedicines* **2023**, *11*, 136. [[CrossRef](#)]
247. Yokoyama, Y.; Kitamura, A.; Seino, S.; Kim, H.; Obuchi, S.; Kawai, H.; Hirano, H.; Watanabe, Y.; Motokawa, K.; Narita, M.; et al. Association of nutrient-derived dietary patterns with sarcopenia and its components in community-dwelling older Japanese: A cross-sectional study. *Nutr. J.* **2021**, *20*, 7. [[CrossRef](#)]
248. Rondanelli, M.; Cereda, E.; Klersy, C.; Faliva, M.A.; Peroni, G.; Nichetti, M.; Gasparri, C.; Iannello, G.; Spadaccini, D.; Infantino, V.; et al. Improving rehabilitation in sarcopenia: A randomized-controlled trial utilizing a muscle-targeted food for special medical purposes. *J. Cachexia Sarcopenia Muscle* **2020**, *11*, 1535–1547. [[CrossRef](#)]
249. Boirie, Y.; Guillet, C. Fast digestive proteins and sarcopenia of aging. *Curr. Opin. Clin. Nutr. Metab. Care* **2018**, *21*, 37–41. [[CrossRef](#)]
250. Beaudart, C.; Buckinx, F.; Rabenda, V.; Gillain, S.; Cavalier, E.; Slomian, J.; Petermans, J.; Reginster, J.Y.; Bruyère, O. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: A systematic review and meta-analysis of randomized controlled trials. *J. Clin. Endocrinol. Metab.* **2014**, *99*, 4336–4345. [[CrossRef](#)]
251. Chang, M.C.; Choo, Y.J. Effects of Whey Protein, Leucine, and Vitamin D Supplementation in Patients with Sarcopenia: A Systematic Review and Meta-Analysis. *Nutrients* **2023**, *15*, 521. [[CrossRef](#)]
252. Zhang, F.; Li, W. Vitamin D and Sarcopenia in the Senior People: A Review of Mechanisms and Comprehensive Prevention and Treatment Strategies. *Ther. Clin. Risk Manag.* **2024**, *20*, 577–595. [[CrossRef](#)] [[PubMed](#)]
253. Houston, D.K.; Cesari, M.; Ferrucci, L.; Cherubini, A.; Maggio, D.; Bartali, B.; Johnson, M.A.; Schwartz, G.G.; Kritchevsky, S.B. Association between vitamin D status and physical performance: The InCHIANTI study. *J. Gerontol. A Biol. Sci. Med. Sci.* **2007**, *62*, 440–446. [[CrossRef](#)] [[PubMed](#)]
254. Mizuno, T.; Hosoyama, T.; Tomida, M.; Yamamoto, Y.; Nakamichi, Y.; Kato, S.; Kawai-Takaishi, M.; Ishizuka, S.; Nishita, Y.; Tange, C.; et al. Influence of vitamin D on sarcopenia pathophysiology: A longitudinal study in humans and basic research in knockout mice. *J. Cachexia Sarcopenia Muscle* **2022**, *13*, 2961–2973. [[CrossRef](#)] [[PubMed](#)]
255. Aspell, N.; Laird, E.; Healy, M.; Lawlor, B.; O’Sullivan, M. Vitamin D Deficiency Is Associated With Impaired Muscle Strength And Physical Performance In Community-Dwelling Older Adults: Findings From The English Longitudinal Study Of Ageing. *Clin. Interv. Aging* **2019**, *14*, 1751–1761. [[CrossRef](#)]
256. Shahatah, F.A.; Hill, T.R.; Fairley, A.; Watson, A.W. Ultra-Processed Food Intakes and Health Outcomes in Adults Older Than 60 Years: A Systematic Review. *Nutr. Rev.* **2025**, *83*, 1711–1724. [[CrossRef](#)]
257. Pagliai, G.; Dinu, M.; Madarena, M.P.; Bonaccio, M.; Iacoviello, L.; Sofi, F. Consumption of ultra-processed foods and health status: A systematic review and meta-analysis. *Br. J. Nutr.* **2021**, *125*, 308–318. [[CrossRef](#)]
258. Parlak Baskurt, H.; Yardımcı, H. Consumption of ultra-processed foods can accelerate age-related appearance of sarcopenia. *Biogerontology* **2025**, *26*, 112. [[CrossRef](#)]
259. Martínez-Arnau, F.M.; Fonfría-Vivas, R.; Buigues, C.; Castillo, Y.; Molina, P.; Hoogland, A.J.; van Doesburg, F.; Pruijboom, L.; Fernández-Garrido, J.; Cauli, O. Effects of Leucine Administration in Sarcopenia: A Randomized and Placebo-controlled Clinical Trial. *Nutrients* **2020**, *12*, 932. [[CrossRef](#)]
260. Abe, S.; Ezaki, O.; Suzuki, M. Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Increase Muscle Strength and Function in Frail Elderly Adults in a Randomized Controlled Trial. *J. Nutr.* **2016**, *146*, 1017–1026. [[CrossRef](#)]

261. Tieland, M.; Trouwborst, I.; Clark, B.C. Skeletal muscle performance and ageing. *J. Cachexia Sarcopenia Muscle* **2018**, *9*, 3–19. [[CrossRef](#)]
262. Bukhari, S.S.; Phillips, B.E.; Wilkinson, D.J.; Limb, M.C.; Rankin, D.; Mitchell, W.K.; Kobayashi, H.; Greenhaff, P.L.; Smith, K.; Atherton, P.J. Intake of low-dose leucine-rich essential amino acids stimulates muscle anabolism equivalently to bolus whey protein in older women at rest and after exercise. *Am. J. Physiol. Endocrinol. Metab.* **2015**, *308*, E1056–E1065. [[CrossRef](#)] [[PubMed](#)]
263. Rondanelli, M.; Klersy, C.; Terracol, G.; Talluri, J.; Maugeri, R.; Guido, D.; Faliva, M.A.; Solerte, B.S.; Fioravanti, M.; Lukaski, H.; et al. Whey protein, amino acids, and vitamin D supplementation with physical activity increases fat-free mass and strength, functionality, and quality of life and decreases inflammation in sarcopenic elderly. *Am. J. Clin. Nutr.* **2016**, *103*, 830–840. [[CrossRef](#)] [[PubMed](#)]
264. Bo, Y.; Liu, C.; Ji, Z.; Yang, R.; An, Q.; Zhang, X.; You, J.; Duan, D.; Sun, Y.; Zhu, Y.; et al. A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized controlled trial. *Clin. Nutr.* **2019**, *38*, 159–164. [[CrossRef](#)] [[PubMed](#)]
265. Roager, H.M.; Vogt, J.K.; Kristensen, M.; Hansen, L.B.S.; Ibrügger, S.; Mærkedahl, R.B.; Bahl, M.I.; Lind, M.V.; Nielsen, R.L.; Frøkiær, H.; et al. Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: A randomised cross-over trial. *Gut* **2019**, *68*, 83–93. [[CrossRef](#)]
266. Yuan, C. Molecular mechanisms and therapeutic strategies of gut microbiota modulation in Sarcopenia (Review). *Oncol. Lett.* **2025**, *29*, 104. [[CrossRef](#)]
267. Rooks, D.S.; Laurent, D.; Praestgaard, J.; Rasmussen, S.; Bartlett, M.; Tankó, L.B. Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. *J. Cachexia Sarcopenia Muscle* **2017**, *8*, 727–734. [[CrossRef](#)]
268. Rooks, D.; Petricoul, O.; Praestgaard, J.; Bartlett, M.; Laurent, D.; Roubenoff, R. Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. *J. Cachexia Sarcopenia Muscle* **2020**, *11*, 1525–1534. [[CrossRef](#)]
269. Rooks, D.; Praestgaard, J.; Hariry, S.; Laurent, D.; Petricoul, O.; Perry, R.G.; Lach-Trifilieff, E.; Roubenoff, R. Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study. *J. Am. Geriatr. Soc.* **2017**, *65*, 1988–1995. [[CrossRef](#)]
270. Rooks, D.; Swan, T.; Goswami, B.; Filosa, L.A.; Bunte, O.; Panchaud, N.; Coleman, L.A.; Miller, R.R.; Garcia Garayoa, E.; Praestgaard, J.; et al. Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial. *JAMA Netw. Open* **2020**, *3*, e2020836. [[CrossRef](#)]
271. Rondanelli, M.; Gasparri, C.; Cavioni, A.; Sivieri, C.; Barrile, G.C.; Mansueto, F.; Perna, S. A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial. *Nutrients* **2024**, *16*, 1369. [[CrossRef](#)] [[PubMed](#)]
272. Cruz-Jentoft, A.J. Beta-Hydroxy-Beta-Methyl Butyrate (HMB): From Experimental Data to Clinical Evidence in Sarcopenia. *Curr. Protein Pept. Sci.* **2018**, *19*, 668–672. [[CrossRef](#)] [[PubMed](#)]
273. Rossi, A.P.; D’Introno, A.; Rubele, S.; Caliari, C.; Gattazzo, S.; Zoico, E.; Mazzali, G.; Fantin, F.; Zamboni, M. The Potential of  $\beta$ -Hydroxy- $\beta$ -Methylbutyrate as a New Strategy for the Management of Sarcopenia and Sarcopenic Obesity. *Drugs Aging* **2017**, *34*, 833–840. [[CrossRef](#)]
274. Phillips, S.M.; Lau, K.J.; D’Souza, A.C.; Nunes, E.A. An umbrella review of systematic reviews of  $\beta$ -hydroxy- $\beta$ -methyl butyrate supplementation in ageing and clinical practice. *J. Cachexia Sarcopenia Muscle* **2022**, *13*, 2265–2275. [[CrossRef](#)] [[PubMed](#)]
275. Roschel, H.; Hayashi, A.P.; Fernandes, A.L.; Jambassi-Filho, J.C.; Hevia-Larraín, V.; de Capitani, M.; Santana, D.A.; Gonçalves, L.S.; de Sá-Pinto, A.L.; Lima, F.R.; et al. Supplement-based nutritional strategies to tackle frailty: A multifactorial, double-blind, randomized placebo-controlled trial. *Clin. Nutr.* **2021**, *40*, 4849–4858. [[CrossRef](#)]
276. Jyväkorpi, S.K.; Ramel, A.; Strandberg, T.E.; Piotrowicz, K.; Błaszczuk-Bębenek, E.; Urtamo, A.; Rempe, H.M.; Geirsdóttir, Ó.; Vágnerová, T.; Billot, M.; et al. The sarcopenia and physical frailty in older people: Multi-component treatment strategies (SPRINTT) project: Description and feasibility of a nutrition intervention in community-dwelling older Europeans. *Eur. Geriatr. Med.* **2021**, *12*, 303–312. [[CrossRef](#)]
277. Vikberg, S.; Sörlén, N.; Brandén, L.; Johansson, J.; Nordström, A.; Hult, A.; Nordström, P. Effects of Resistance Training on Functional Strength and Muscle Mass in 70-Year-Old Individuals with Pre-sarcopenia: A Randomized Controlled Trial. *J. Am. Med. Dir. Assoc.* **2019**, *20*, 28–34. [[CrossRef](#)]
278. Li, Z.; Cui, M.; Yu, K.; Zhang, X.W.; Li, C.W.; Nie, X.D.; Wang, F. Effects of nutrition supplementation and physical exercise on muscle mass, muscle strength and fat mass among sarcopenic elderly: A randomized controlled trial. *Appl. Physiol. Nutr. Metab.* **2021**, *46*, 494–500. [[CrossRef](#)]
279. Hsu, K.J.; Liao, C.D.; Tsai, M.W.; Chen, C.N. Effects of Exercise and Nutritional Intervention on Body Composition, Metabolic Health, and Physical Performance in Adults with Sarcopenic Obesity: A Meta-Analysis. *Nutrients* **2019**, *11*, 2163. [[CrossRef](#)]

280. Lin, C.C.; Shih, M.H.; Chen, C.D.; Yeh, S.L. Effects of adequate dietary protein with whey protein, leucine, and vitamin D supplementation on sarcopenia in older adults: An open-label, parallel-group study. *Clin. Nutr.* **2021**, *40*, 1323–1329. [[CrossRef](#)]
281. Bauer, J.M.; Verlaan, S.; Bautmans, I.; Brandt, K.; Donini, L.M.; Maggio, M.; McMurdo, M.E.; Mets, T.; Seal, C.; Wijers, S.L.; et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: A randomized, double-blind, placebo-controlled trial. *J. Am. Med. Dir. Assoc.* **2015**, *16*, 740–747. [[CrossRef](#)]
282. Andreo-López, M.C.; Contreras-Bolívar, V.; García-Fontana, B.; García-Fontana, C.; Muñoz-Torres, M. The Influence of the Mediterranean Dietary Pattern on Osteoporosis and Sarcopenia. *Nutrients* **2023**, *15*, 3224. [[CrossRef](#)]
283. Dominguez, L.J.; Veronese, N.; Smith, L.; Ragusa, F.S.; Schirò, P.; Di Bella, G.; Barbagallo, M. Associations Between Adherence to the Mediterranean Diet and Incident Sarcopenia in Prospective Cohort Studies. *Nutrients* **2025**, *17*, 313. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.